Novartis (NVS) 6-K 18 Jul 24 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2024
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Registrant Name	Novartis AG
Entity Central Index Key	0001114448
Current Fiscal Year End Date	--12-31

Consolidated income statements

Consolidated income statements - USD ($) shares in Millions, $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Net sales from continuing operations		$ 12,512	$ 11,437	$ 24,341	$ 22,235
Other revenues		360	308	651	557
Cost of goods sold		(3,173)	(3,342)	(6,269)	(6,333)
Gross profit from continuing operations		9,699	8,403	18,723	16,459
Selling, general and administration		(3,091)	(3,091)	(5,931)	(5,982)
Research and development		(2,367)	(2,304)	(4,788)	(4,879)
Other income		273	135	522	1,098
Other expense		(500)	(336)	(1,139)	(1,271)
Operating income from continuing operations		4,014	2,807	7,387	5,425
Loss from associated companies		(2)	(2)	(31)	(4)
Interest expense		(246)	(216)	(467)	(416)
Other financial income and expense		75	85	81	189
Income before taxes		3,841	2,674	6,970	5,194
Income taxes		(595)	(403)	(1,036)	(773)
Net income from continuing operations		3,246	2,271	5,934	4,421
Net income from discontinued operations			46		190
Net income		3,246	2,317	5,934	4,611
Attributable to
Shareholders of Novartis AG		3,246	2,316	5,934	4,609
Non-controlling interests		$ 0	$ 1	$ 0	$ 2
Basic earnings per share [abstract]
Weighted average number of ordinary shares outstanding		2,033	2,083	2,038	2,097
Basic earnings (loss) per share from continuing operation	[1]	$ 1.60	$ 1.09	$ 2.91	$ 2.12
Basic earnings (loss) per share from discontinued operations	[1]		0.02		0.08
Basic earnings per share	[1]	$ 1.60	$ 1.11	$ 2.91	$ 2.20
Diluted earnings per share [abstract]
Adjusted weighted average number of ordinary shares outstanding		2,046	2,095	2,052	2,109
Diluted earnings (loss) per share from continuing operations	[1]	$ 1.59	$ 1.09	$ 2.89	$ 2.10
Diluted earnings (loss) per share from discontinued operations	[1]		0.02		0.09
Diluted earnings per share	[1]	$ 1.59	$ 1.11	$ 2.89	$ 2.19
[1]Earnings per share (EPS) is calculated on the amount of net income attributable to shareholders of Novartis AG.

Consolidated statements of comp

Consolidated statements of comprehensive income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Net income	$ 3,246	$ 2,317	$ 5,934	$ 4,611
Other comprehensive income to be eventually recycled into the consolidated income statement
Net investment hedge	14	6	51	(29)
Currency translation effects	40	216	(1,364)	522
Total of items to eventually recycle	54	222	(1,313)	493
Other comprehensive income never to be recycled into the consolidated income statement
Actuarial gains/losses from defined benefit plans, net of taxes	57	(1)	136	(59)
Fair value adjustments on equity securities, net of taxes	94	(2)	119	(46)
Total of items never to be recycled	151	(3)	255	(105)
Total other comprehensive income	205	219	(1,058)	388
Total comprehensive income	3,451	2,536	4,876	4,999
Attributable to
Shareholders of Novartis AG	3,453	2,535	4,880	4,996
Comprehensive income, attributable to non-controlling interests	(2)	1	(4)	3
Continuing operations
Attributable to
Shareholders of Novartis AG	$ 3,453	2,502	$ 4,880	4,761
Discontinued operations
Attributable to
Shareholders of Novartis AG		$ 33		$ 235

Consolidated balance sheets

Consolidated balance sheets - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Non-current assets [abstract]
Property, plant and equipment	$ 9,254	$ 9,514
Right-of-use assets	1,368	1,410
Goodwill	25,234	23,341
Intangible assets other than goodwill	27,775	26,879
Investments in associated companies	103	205
Deferred tax assets	4,400	4,309
Financial assets	2,023	2,607
Other non-current assets	1,655	1,199
Total non-current assets	71,812	69,464
Current assets [abstract]
Inventories	5,747	5,913
Trade receivables	8,228	7,107
Income tax receivable	252	426
Marketable securities, commodities, time deposits and derivative financial instruments	532	1,035
Cash and cash equivalents	7,903	13,393
Other current assets	3,031	2,607
Total current assets	25,693	30,481
Total assets	97,505	99,945
Equity [abstract]
Share capital	793	825
Treasury shares	(25)	(41)
Reserves	40,965	45,883
Equity attributable to Novartis AG shareholders	41,733	46,667
Non-controlling interests	169	83
Total equity	41,902	46,750
Non-current liabilities [abstract]
Financial debts	19,663	18,436
Lease liabilities	1,560	1,598
Deferred tax liabilities	2,456	2,248
Provisions and other non-current liabilities	4,312	4,523
Total non-current liabilities	27,991	26,805
Current liabilities [abstract]
Trade payables	4,146	4,926
Financial debts and derivative financial instruments	7,532	6,175
Lease liabilities	232	230
Current income tax liabilities	1,919	1,893
Provisions and other current liabilities	13,783	13,166
Total current liabilities	27,612	26,390
Total liabilities	55,603	53,195
Total equity and liabilities	$ 97,505	$ 99,945

Consolidated statements of chan

Consolidated statements of changes in equity - USD ($) $ in Millions	Total	Equity attributable to owners of parent [member]	Share capital	Treasury shares	Retained earnings	Total value adjustments	Non-controlling interests [member]
Equity at beginning of period at Dec. 31, 2022	$ 59,423	$ 59,342	$ 890	$ (92)	$ 63,540	$ (4,996)	$ 81
Net income	4,611	4,609			4,609		2
Other comprehensive income	388	387				387	1
Total comprehensive income	4,999	4,996			4,609	387	3
Dividends	(7,255)	(7,255)			(7,255)
Purchase of treasury shares	(5,888)	(5,888)		(35)	(5,853)
Reduction of share capital			(48)	68	(20)
Exercise of options and employee transactions, equity impact	153	153		2	151
Equity-based compensation	433	433		5	428
Taxes on treasury shares	8	8			8
Fair value adjustments on equity securities sold, reclassified to retained earnings					16	(16)
Other movements	58	58			58
Total of other equity movements	(12,491)	(12,491)	(48)	40	(12,467)	(16)
Equity at end of period at Jun. 30, 2023	51,931	51,847	842	(52)	55,682	(4,625)	84
Equity at beginning of period at Mar. 31, 2023	52,142	52,059	842	(36)	56,089	(4,836)	83
Net income	2,317	2,316			2,316		1
Other comprehensive income	219	219				219	0
Total comprehensive income	2,536	2,535			2,316	219	1
Purchase of treasury shares	(3,011)	(3,011)		(17)	(2,994)
Equity-based compensation	242	242		1	241
Fair value adjustments on equity securities sold, reclassified to retained earnings					8	(8)
Other movements	22	22			22
Total of other equity movements	(2,747)	(2,747)		(16)	(2,723)	(8)
Equity at end of period at Jun. 30, 2023	51,931	51,847	842	(52)	55,682	(4,625)	84
Equity at beginning of period at Dec. 31, 2023	46,750	46,667	825	(41)	49,649	(3,766)	83
Net income	5,934	5,934			5,934		0
Other comprehensive income	(1,058)	(1,054)				(1,054)	(4)
Total comprehensive income	4,876	4,880			5,934	(1,054)	(4)
Dividends	(7,624)	(7,624)			(7,624)
Purchase of treasury shares	(2,813)	(2,813)		(15)	(2,798)
Reduction of share capital			(32)	26	6
Exercise of options and employee transactions, equity impact	(35)	(35)			(35)
Equity-based compensation	552	552		5	547
Shares delivered to divested business employees, equity impact Sandoz	12	12			12
Taxes on treasury shares	8	8			8
Fair value adjustments on equity securities sold, reclassified to retained earnings					51	(51)
Impact of change in ownership of consolidated entities	62	(28)			(28)		90
Other movements	114	114			114
Total of other equity movements	(9,724)	(9,814)	(32)	16	(9,747)	(51)	90
Equity at end of period at Jun. 30, 2024	41,902	41,733	793	(25)	45,836	(4,871)	169
Equity at beginning of period at Mar. 31, 2024	39,756	39,675	793	(17)	43,834	(4,935)	81
Net income	3,246	3,246			3,246		0
Other comprehensive income	205	207				207	(2)
Total comprehensive income	3,451	3,453			3,246	207	(2)
Purchase of treasury shares	(1,672)	(1,672)		(9)	(1,663)
Exercise of options and employee transactions, equity impact	(1)	(1)			(1)
Equity-based compensation	268	268		1	267
Shares delivered to divested business employees, equity impact Sandoz	2	2			2
Taxes on treasury shares	(12)	(12)			(12)
Fair value adjustments on equity securities sold, reclassified to retained earnings					143	(143)
Impact of change in ownership of consolidated entities	62	(28)			(28)		90
Other movements	48	48			48
Total of other equity movements	(1,305)	(1,395)		(8)	(1,244)	(143)	90
Equity at end of period at Jun. 30, 2024	$ 41,902	$ 41,733	$ 793	$ (25)	$ 45,836	$ (4,871)	$ 169

Consolidated cash flow statemen

Consolidated cash flow statements - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Net income from continuing operations	$ 3,246	$ 2,271	$ 5,934	$ 4,421
Reversal of non-cash items and other adjustments	2,400	2,567	4,897	5,249
Dividends received from associated companies and others	1		1	1
Interest received	71	117	235	373
Interest paid	(255)	(220)	(402)	(335)
Other financial receipts		(53)		27
Other financial payments	(65)	(4)	(94)	(10)
Income taxes paid	(473)	(973)	(1,049)	(1,268)
Net cash flows from operating activities before working capital and provision changes	4,925	3,705	9,522	8,458
Payments out of provisions and other net cash movements in non-current liabilities	(288)	(243)	(631)	(926)
Change in net current assets and other operating cash flow items	238	55	(1,751)	(1,163)
Net cash flows from operating activities from continuing operations	4,875	3,517	7,140	6,369
Net cash flows from operating activities from discontinued operations		59		164
Total net cash flows from operating activities	4,875	3,576	7,140	6,533
Purchases of property, plant and equipment	(260)	(225)	(487)	(393)
Proceeds from sale of property, plant and equipment	37	4	38	22
Purchases of intangible assets	(468)	(673)	(1,397)	(894)
Proceeds from sale of intangible assets	20		20	130
Purchases of financial assets	(45)	(26)	(92)	(66)
Proceeds from sale of financial assets	647	47	710	110
Divestments and acquisitions of interests in associated companies, net	(12)	(2)	4	(5)
Acquisitions and divestments of businesses, net	(3,319)	(84)	(3,598)	(107)
Purchases of marketable securities, commodities and time deposits	(237)	(4)	(240)	(69)
Proceeds from sale of marketable securities, commodities and time deposits	430	3	936	11,017
Net cash flows (used in)/from investing activities from continuing operations	(3,207)	(960)	(4,106)	9,745
Net cash flows used in investing activities from discontinued operations		(93)		(177)
Total net cash flows from investing activities	(3,207)	(1,053)	(4,106)	9,568
Dividends paid to shareholders of Novartis AG	(2,417)		(7,624)	(7,255)
Purchases of treasury shares	(1,616)	(2,957)	(2,715)	(5,843)
Proceeds from exercised options and other treasury share transactions, net	25		25	159
Increase in non-current financial debts	2,473		2,473
Repayments of the current portion of non-current financial debts	(2,150)		(2,150)
Change in current financial debts	569	(709)	1,789	290
Payments of lease liabilities	(59)	(65)	(126)	(131)
Payments from changes in ownership interests in consolidated subsidiaries	(47)		(47)
Other financing cash flows, net	22	(35)	11	18
Net cash flows used in financing activities from continuing operations	(3,200)	(3,766)	(8,364)	(12,762)
Net cash flows from/(used in) financing activities from discontinued operations		129		(77)
Total net cash flows used in financing activities	(3,200)	(3,637)	(8,364)	(12,839)
Net change in cash and cash equivalents before effect of exchange rate changes	(1,532)	(1,114)	(5,330)	3,262
Effect of exchange rate changes on cash and cash equivalents	(34)	(1)	(160)	106
Net change in cash and cash equivalents	(1,566)	(1,115)	(5,490)	3,368
Cash and cash equivalents at beginning of period	9,469	12,000	13,393	7,517
Cash and cash equivalents at end of period	$ 7,903	$ 10,885	$ 7,903	$ 10,885

Basis of preparation

Basis of preparation	6 Months Ended
	Jun. 30, 2024
Basis of preparation [abstract]
Disclosure of basis of preparation of financial statements [text block]	1. Basis of preparation The consolidated financial statements of the Company are prepared in accordance with International Financial Reporting Standards (IFRS ® ® At the Novartis AG Extraordinary General Meeting, held on September 15, 2023, our shareholders approved the spin-off of the Sandoz business. Following the shareholder approval IFRS Accounting Standards required the Sandoz Division and selected portions of corporate activities attributable to Sandoz’s business, as well as certain expenses related to the spin-off (the “Sandoz business”) to be reported as discontinued operations in the consolidated financial statements. As a result, the Sandoz business has been presented as discontinued operations in the condensed interim consolidated financial statements. This requires the three month and six month period ended June 30, 2023, consolidated income statement, consolidated statement of comprehensive income and consolidated statement of cash flows to present separately continuing operations from discontinued operations. For further information and disclosures, refer to Note 3 and Note 11.

Accounting policies

Accounting policies	6 Months Ended
	Jun. 30, 2024
Selected critical accounting policies [abstract]
Disclosure of material accounting policy information [text block]	2. Accounting policies The Company’s accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2023 Annual Report and conform with IFRS Accounting Standards as issued by the International Accounting Standards Board. The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. As disclosed in the 2023 Annual Report, goodwill, and acquired In-Process Research & Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Company’s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Company’s results of operations and financial condition. The Company’s activities are not subject to significant seasonal fluctuations. Status of adoption of significant new or amended IFRS standards or interpretations No new IFRS Accounting Standards were adopted by the Company in 2024. In addition, new IFRS Accounting Standards amendments or interpretations that became effective in 2024 did not have a material impact on the Company’s consolidated financial statements. Based on the Company’s assessment, there are no IFRS Accounting Standards, amendments or interpretations not yet effective in 2024 that would be expected to have a material impact on the Company’s consolidated financial statements. In the second quarter of 2024, the following new IFRS Accounting Standard, which is not yet effective, was issued by the International Accounting Standards Board: IFRS 18 Presentation and Disclosures in Financial Statements IFRS 18 Presentation and Disclosure in Financial Statements was issued by the International Accounting Standards Board in April 2024. IFRS 18 is effective on January 1, 2027, and is required to be applied retrospectively to comparative periods presented, with early adoption permitted. IFRS 18, upon adoption replaces IAS Standards 1 - Presentation of Financial Statements. IFRS 18 sets out new requirements focused on improving financial reporting by: • requiring additional defined structure to the statement of profit or loss (i.e. consolidated statement of income), to reduce diversity in the reporting, by requiring five categories (operating, investing, financing, income taxes and discontinued operations) and defined subtotals and totals (operating income, income before financing, income taxes and net income), • requiring disclosures in the notes to the financial statements about management-defined performance measures (i.e. non-IFRS measures), and • adding new principles for aggregation and disaggregation of information in the primary financial statements and notes. IFRS 18 will not impact the recognition or measurement of items in the financial statements, but it might change what an entity reports as its ‘operating profit or loss’, due to the classification of certain income and expense items between the five categories of the consolidated income statement. It might also change what an entity reports as operating activities, investing activities and financing activities within the statement of cash flows, due to the change in classification of certain cash flow items between these three categories of the cash flows statement. Novartis is currently assessing the impact of adopting IFRS 18.

Significant acquisition of busi

Significant acquisition of businesses	6 Months Ended
	Jun. 30, 2024
Disclosure of significant transactions [abstract]
Significant transactions	3. Significant acquisitions of businesses and spin-off of Sandoz business The Company applied the acquisition method of accounting for businesses acquired, and did not elect to apply the optional concentration test to account for acquired business as an asset separately acquired. Significant acquisitions of businesses – 2024 Acquisition of Mariana Oncology On May 2, 2024, Novartis acquired Mariana Oncology, a preclinical-stage US based biotechnology company focused on developing novel radioligand therapies (RLTs) with a portfolio of RLT programs across a range of solid tumor indications. The purchase price consisted of a cash payment of USD 1.1 billion and potential additional milestones of up to USD 0.8 billion, which the Mariana Oncology shareholders are eligible to receive upon the achievement of specified milestones. The fair value of the total purchase consideration was USD 1.3 billion, consisting of a cash payment of USD 1.1 billion and the fair value of contingent consideration of USD 0.2 billion. The preliminary purchase price allocation resulted in net identifiable assets of USD 0.7 billion, consisting primarily of IPR&D intangible assets of USD 0.3 billion, other intangible assets (scientific infrastructure) of USD 0.4 billion, cash and cash equivalents of USD 0.1 billion and net deferred tax liabilities of USD 0.1 billion. Goodwill amounted to USD 0.6 billion. The results of operations since the date of acquisition were not material. Acquisition of MorphoSys AG On February 5, 2024, Novartis entered into an agreement to acquire MorphoSys AG (MorphoSys), a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. The acquisition of MorphoSys adds to our oncology pipeline pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or lymphomasis. On April 11, 2024, Novartis, through a subsidiary, commenced a voluntary public takeover offer (the “Offer”) to acquire all outstanding shares of MorphoSys for EUR 68 per share, representing a total consideration of approximately EUR 2.6 billion in cash on a fully diluted basis. The settlement of the Offer was conditional on a minimum acceptance threshold of 65 percent of MorphoSys outstanding shares. Novartis purchased during the Offer acceptance period MorphoSys shares on the market for a total amount of EUR 0.3 billion (USD 0.3 billion). The closing conditions of the Offer, including the minimum acceptance threshold of 65 percent were fulfilled by the end of the Offer acceptance period, and the acquisition of MorphoSys closed on May 23, 2024, with the settlement payment amounting to EUR 1.7 billion (USD 1.9 billion) to the MorphoSys shareholders for their tendered shares. Subsequent to May 23, 2024, Novartis acquired additional MorphoSys outstanding shares through the Germany statutory two-week extension period of the Offer (ending on May 30, 2024) for EUR 0.3 billion (USD 0.3 billion). As a result, as at May 30, 2024, Novartis held 89.7 percent of the total outstanding share capital of MorphoSys. Total cash paid for the MorphoSys shares purchased by Novartis through to the end of the statutory two-week extension period of the Offer amounted to EUR 2.3 billion (USD 2.5 billion). Non-controlling interests represented 10.3 percent of MorphoSys outstanding shares amounting to USD 0.1 billion and were recognized in equity. In June 2024, Novartis purchased outside the Offer an additional 1.7 percent of MorphoSys shares for EUR 44 million (USD 47 million). As a result, at June 30, 2024, non-controlling interests in equity were reduced by USD 17 million and Novartis held approximately 91.4 percent of outstanding MorphoSys shares and non-controlling interests represented approximately 8.6 percent of the outstanding MorphoSys shares. On July 4, 2024, Novartis filed a public delisting purchase offer to delist the MorphoSys shares admitted to trading on regulated markets and acquire all MorphoSys AG shares and ADS not held directly by Novartis. The purchase price allocation is preliminary pending primarily the outcome of Novartis analysis of certain clinical trial data readouts that became available prior to the closing date. The fair value of the total purchase consideration for the 89.7 percent stake was USD 2.5 billion (including cash acquired). The preliminary purchase price allocation resulted in net identifiable assets of USD 1.0 billion, consisting primarily of IPR&D intangible assets of USD 1.1 billion, financial investments and other receivables of USD 0.6 billion, marketable securities of USD 0.4 billion, cash and cash equivalents of USD 0.2 billion, financial debt to third parties of USD 0.9 billion, net deferred tax liabilities of USD 0.1 billion, and other net liabilities of USD 0.2 billion. Non-controlling interests amounted USD 0.1 billion, which were recognized at the non-controlling interest’s proportionate share of MorphoSys identifiable net assets. Goodwill amounted to USD 1.6 billion. The finalization of the preliminary purchase price allocation may lead to a change to the allocation between the identifiable assets, mainly intangible assets - IPR&D and net deferred taxes, and goodwill. The results of operations since the date of acquisition were not material. Significant acquisitions of businesses – 2023 Acquisition of DTx Pharma Inc. In the second quarter of 2023, Novartis entered into an agreement to acquire all outstanding shares of DTx Pharma Inc. (DTx), a US based, pre-clinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications. DTx’s lead program, DTx-1252 targets the root cause of CMT1A—the overexpression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally. The transaction also includes two additional pre-clinical programs for other neuroscience indications. The transaction closed on July 14, 2023. The purchase price consisted of a cash payment of USD 0.6 billion and potential additional milestones of up to USD 0.5 billion, which the DTx shareholders are eligible to receive upon the achievement of specified milestones. The fair value of the total purchase consideration was USD 0.6 billion. The amount consisted of a cash payment of USD 0.6 billion and the fair value of contingent consideration of USD 30 million, which DTx shareholders are eligible to receive upon the achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 0.4 billion, consisting primarily of IPR&D intangible assets of USD 0.4 billion, cash of USD 0.1 billion and net deferred tax liabilities of USD 0.1 billion. Goodwill amounted to USD 0.2 billion. The 2023 results of operations since the date of acquisition were not material. Acquisition of Chinook Therapeutics, Inc. On June 12, 2023, Novartis entered into an agreement to acquire all outstanding shares of Chinook Therapeutics, Inc. (Chinook Therapeutics), a US based clinical stage biopharmaceutical company with two late-stage medicines in development for rare, severe chronic kidney diseases. The acquisition closed on August 11, 2023. The purchase price consisted of a cash payment of USD 3.2 billion and potential additional payments of up to USD 0.3 billion, which Chinook Therapeutics shareholders are eligible to receive upon the achievement of specified milestones. The fair value of the total purchase consideration was USD 3.3 billion. The amount consisted of an upfront cash payment of USD 3.2 billion and the fair value of contingent consideration of USD 0.1 billion, which Chinook Therapeutics shareholders are eligible to receive upon achievement of specified milestones. The purchase price allocation resulted in net identifiable assets of USD 2.4 billion, consisting primarily of IPR&D intangible assets of USD 2.5 billion, net deferred tax liabilities of USD 0.4 billion and other net assets of USD 0.3 billion, including cash of USD 0.1 billion. Goodwill amounted to USD 0.9 billion. The 2023 results of operations since the date of acquisition were not material. Fair value of assets and liabilities arising from acquisitions of businesses The following table presents the fair value of the assets and liabilities acquired through acquisitions of business and the total purchase consideration for the first half of 2024, and for the year ended December 31, 2023: Jun 30, Dec 31, Property, plant and equipment 23 18 Right-of-use assets 32 16 In-process research and development 1 746 2 931 Other intangible assets 1 419 15 Deferred tax assets 315 34 Non-current financial and other assets 421 164 Trade receivable and financial and Cash and cash equivalents 236 226 Deferred tax liabilities -600 -474 Current and non-current financial debts -905 Current and non-current lease liabilities -41 -51 Trade payables and other liabilities -289 -231 Net identifiable assets acquired 2 015 2 831 Non-controlling interests -108 Goodwill 2 198 1 094 Total purchase consideration for acquisitions of businesses 4 105 3 925 1 The significant business acquisitions in the first half of 2024 were of MorphoSys and Mariana Oncology, both in the second quarter of 2024. The goodwill arising out of the first half of 2024 acquisitions is not tax deductible and it is attributable to the synergies, accounting for deferred tax liabilities on acquired assets, and the assembled workforce, and in addition for MorphoSys the relief from royalties. In 2023, the significant business acquisitions were the acquisition of DTx Pharma and Chinook Therapeutics. There were no significant acquisitions of businesses in the first half of 2023. The goodwill arising out of these acquisitions is attributable to the synergies, the accounting for deferred tax liabilities on the acquired assets and the assembled workforce. In 2023, no goodwill was tax deductible. Spin-off of Sandoz business – 2023 Completion of the spin-off of the Sandoz business through a dividend in kind distribution to Novartis AG shareholders On July 18, 2023, Novartis announced that its Board of Directors had unanimously endorsed the proposed separation of the Sandoz business to create an independent company by way of a spin-off and to seek shareholder approval for the spin-off of the Sandoz business into a separately traded standalone company, following the complete structural separation of the Sandoz business into a standalone company (the Sandoz business or Sandoz Group AG) and subject to the satisfaction of certain conditions and Novartis AG shareholder approval. At the EGM held on September 15, 2023, Novartis AG shareholders approved a special distribution by way of a dividend in kind to effect the spin-off of Sandoz Group AG, subject to the completion of certain conditions precedent to the distribution. Upon shareholder approval, the Sandoz business was reported as discontinued operations and the distribution liability was recognized at its fair value, which exceeded the carrying value of the Sandoz business net assets. The conditions precedent to the spin-off were met and on October 3, 2023 the spin-off of the Sandoz business was effected by way of a distribution of a dividend in kind of Sandoz Group AG shares to Novartis AG shareholders and American Depositary Receipt (ADR) holders (the Distribution). Through the Distribution, each Novartis AG shareholder received 1 Sandoz Group AG share for every 5 Novartis AG shares and each Novartis ADR holder received 1 Sandoz ADR for every 5 Novartis ADR that they held at the close of business on October 3, 2023. As of October 4, 2023, the shares of Sandoz Group AG have been listed on the SIX Swiss Exchange (SIX) under the stock symbol “SDZ”. On September 18, 2023, the Sandoz business entered into financing arrangements with a group of banks under which on September 28, 2023, it borrowed a total amount of USD 3.3 billion. These borrowings consisted of a bridge loan in EUR (EUR 2.4 billion) and term loans in EUR (EUR 0.2 billion) and USD (USD 0.5 billion). In addition, the Sandoz business borrowed approximately USD 0.4 billion under a number of local bilateral facilities in different countries. This resulted in a total gross debt of USD 3.7 billion. These outstanding borrowings of the Sandoz business legal entities were recognized in the September 30, 2023 consolidated balance sheet within Liabilities related to discontinued operations and within financing activities cash flows from discontinued operations. Prior to the Distribution on October 3, 2023, Sandoz business legal entities paid approximately USD 3.3 billion in cash to Novartis and its affiliates through a series of intercompany transactions. At the Distribution date on October 3, 2023, the dividend in kind distribution liability to effect the Distribution (spin-off) of the Sandoz business amounted to USD 14.0 billion, measured by reference to the October 4, 2023 opening Sandoz Group AG share price and applying a control premium. The dividend in kind distribution liability was recorded as a reduction to equity (retained earnings) and remained in excess of the then carrying value of the Sandoz business net assets, which amounted to USD 8.6 billion. Certain consolidated foundations own Novartis AG dividend-bearing shares that restricts their availability for use by Novartis. These Novartis AG shares are accounted for as treasury shares. Through the Distribution, these foundations received Sandoz Group AG shares representing an approximate 4.31% The total non-taxable, non-cash gain recognized at the Distribution date of the spin-off of the Sandoz business amounted to USD 5.9 billion, which consists of: Oct 3, Net assets derecognized -8 647 Derecognition of distribution liability 13 962 Difference between net assets and distribution liability 5 315 Recognition of Sandoz Group AG shares Currency translation gains recycled into Transaction costs and other items recognized in the consolidated income statement -304 Gain on distribution of Sandoz Group AG to Novartis AG shareholders 5 860 For additional disclosures on discontinued operations, refer to Note 11.

Summary of equity attributable

Summary of equity attributable to Novartis AG shareholders	6 Months Ended
	Jun. 30, 2024
Disclosure of equity [abstract]
Disclosure of equity [text block]	4. Summary of equity attributable to Novartis AG shareholders Number of outstanding shares (in millions) Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions) Note 2024 2023 H1 2024 H1 2023 Balance at beginning of year 2 044.0 2 119.6 46 667 59 342 Shares acquired to be canceled -26.7 -61.3 -2 698 -5 767 Other share purchases -1.1 -1.3 -115 -121 Exercise of options and employee transactions 0.0 2.8 -35 153 Equity-based compensation 8.3 8.5 552 433 Shares delivered to Sandoz employees as a result of the Sandoz spin-off 0.1 12 Taxes on treasury share transactions 8 8 Dividends 4.1 -7 624 -7 255 Net income of the period attributable to shareholders of Novartis AG 5 934 4 609 Other comprehensive income attributable to shareholders of Novartis AG -1 054 387 Impact of change in ownership of consolidated entities -28 Other movements 4.3 114 58 Balance at June 30 2 024.6 2 068.3 41 733 51 847 4.1. The gross dividend to shareholders of Novartis AG amounted to USD 7.6 billion. The net dividend payment to Novartis AG shareholders paid in March 2024 amounted to USD 5.2 billion. The USD 2.4 billion Swiss withholding tax on the gross dividend was paid at its due date in April 2024. 4.2. In December 2021, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 15.0 billion share buyback. The arrangement was updated in July 2022, December 2022, and May 2023, and concluded in June 2023. In June 2023, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase 11.7 million Novartis shares on the second trading line, which concluded in July 2023. In July 2023, Novartis entered into a new irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its new up-to USD 15.0 billion share buyback. In June 2024, Novartis amended the arrangement to repurchase an additional 8.7 million Novartis shares on the second trading line to mitigate deliveries under employee participation programs. Novartis is able to cancel this arrangement but may be subject to a 90-day waiting period under certain conditions. As of June 30, 2024, and December 31, 2023, these waiting period conditions were not applicable and as a result, there was no requirement to record a liability under this arrangement as of June 30, 2024, and December 31, 2023. 4.3. Other movements include, for subsidiaries in hyper-inflationary economies, the impact of the application of IAS Standards 29 “Financial Reporting in Hyperinflationary Economies.”

Financial instruments

Financial instruments	6 Months Ended
	Jun. 30, 2024
Financial Instruments - additional disclosure [abstract]
Disclosure of detailed information about financial instruments [text block]	5. Financial instruments Fair value by hierarchy The following table illustrates the three hierarchical levels for valuing financial instruments at fair value as of June 30, 2024, and December 31, 2023. For additional information on the hierarchies and other matters, please refer to the Consolidated Financial Statements in the 2023 Annual Report, published on January 31, 2024. Level 1 Level 2 Level 3 Total Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Financial assets Cash and cash equivalents Debt securities 50 50 50 50 Total cash and cash equivalents at fair value 50 50 50 50 Marketable securities Fund investments 405 405 Derivative financial instruments 60 355 60 355 Total marketable securities and derivative financial instruments at fair value 405 60 355 465 355 Current contingent consideration receivables 90 65 90 65 Current fund investments and equity securities 34 94 22 31 56 125 Long-term financial investments Debt and equity securities 275 796 7 20 642 616 924 1 432 Fund investments 12 7 191 183 203 190 Non-current contingent consideration receivables 501 553 501 553 Total long-term financial investments at fair value 287 803 7 20 1 334 1 352 1 628 2 175 Associated companies at fair value through profit or loss 101 101 101 101 Financial liabilities Current contingent consideration liabilities -154 -14 -154 -14 Current other financial liabilities -88 -88 Derivative financial instruments -54 -91 -54 -91 Total current financial liabilities at fair value -54 -91 -154 -102 -208 -193 Non-current contingent consideration liabilities -546 -389 -546 -389 In the first half of 2024, there was one transfer of equity securities from Level 3 to Level 1 for USD 3 million due to Initial Public Offering. The fair value of straight bonds amounted to USD 19.4 billion at June 30, 2024 (USD 19.2 billion at December 31, 2023) compared with the carrying amount of USD 21.1 billion at June 30, 2024 (USD 20.6 billion at December 31, 2023). For all other financial assets and liabilities, the carrying amount is a reasonable approximation of the fair value. The carrying amount of financial assets included in the line total long-term financial investments at fair value of USD 1.6 billion at June 30, 2024 (USD 2.2 billion at December 31, 2023) is included in the line “Financial assets” of the consolidated balance sheets. The carrying amount of financial assets included in the line current fund investments and equity securities of USD 56 million at June 30, 2024 (USD 125 million at December 31, 2023) is included in the line “Other current assets” of the consolidated balance sheets. The carrying amount of non-current contingent consideration liabilities of USD 0.5 billion at June 30, 2024 (USD 0.4 billion at December 31, 2023) is included in the line “Provisions and other non-current liabilities” of the consolidated balance sheets. In the second quarter of 2024, consolidated foundations investments in Sandoz AG shares with a fair value of USD 449 million were sold, and the USD 144 million gain on disposal was transferred from other comprehensive income to retained earnings. The fair value of the investment in Sandoz Group AG amounted to USD 61 million at June 30, 2024 (December 31, 2023: USD 595 million) and was sold in the first days of July 2024. The Company’s exposure to financial risks has not changed significantly during the period and there have been no major changes to the risk management department or in any risk management policies.

Details to the consolidated sta

Details to the consolidated statements of cash flows	6 Months Ended
	Jun. 30, 2024
Disclosure of details to the consolidated statements of cash flows [abstract]
Details to the consolidated statements of cash flows	6. Details to the consolidated statements of cash flows 6.1. Non-cash items and other adjustments from continuing operations The following table shows the reversal of non-cash items and other adjustments in the consolidated statements of cash flows. (USD millions) Q2 2024 Q2 2023 Depreciation, amortization and impairments on: Property, plant and equipment 228 213 Right-of-use assets 61 68 Intangible assets 873 1 427 Financial assets 1 -22 29 Change in provisions and other non-current liabilities 204 -53 Losses on disposal on property, plant and equipment; intangible assets; other non-current assets; Equity-settled compensation expense 257 222 Loss from associated companies 2 2 Income taxes 595 403 Net financial expense 171 131 Other -41 39 Total 2 400 2 567 1 (USD millions) H1 2024 H1 2023 Depreciation, amortization and impairments on: Property, plant and equipment 447 465 Right-of-use assets 124 133 Intangible assets 1 905 2 980 Financial assets 1 6 75 Change in provisions and other non-current liabilities 367 362 Losses/(gains) on disposal on property, plant and equipment; intangible assets; other non-current assets; -216 Equity-settled compensation expense 517 412 Loss from associated companies 31 4 Income taxes 1 036 773 Net financial expense 386 227 Other -64 34 Total 4 897 5 249 1 6.2. Total amount of income taxes paid In the first half of 2024, the total amount of income taxes paid by continuing operations was USD 1 049 million (Q2 2024: USD 473 million), and nil by discontinued operations (Q2 2024: nil). In the first half of 2024, the total amount of income taxes paid by the Company was USD 1 049 million (Q2 2024: USD 473 million). In the first half of 2023, the total amount of income taxes paid by continuing operations was USD 1 268 million (Q2 2023: USD 973 million), and by discontinued operations was USD 110 million (Q2 2023: USD 57 million), which was included within “Net cash flows from operating activities from discontinued operations”. In the first half of 2023, the total amount of income taxes paid by the Company was USD 1 378 million (Q2 2023: USD 1 030 million). 6.3. Cash flows from changes in working capital and other operating items included in the net cash flows from operating activities from continuing operations (USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Increase in inventories -18 -185 -146 -546 Increase in trade receivables -501 -447 -1 421 -1 147 (Decrease)/increase in trade payables -142 73 -551 99 Change in other current and non-current assets -105 9 -377 -100 Change in other current liabilities 1 004 605 744 531 Total 238 55 -1 751 -1 163 6.4. Cash flows arising from acquisitions and divestments of businesses, net from continuing operations The following table is a summary of the cash flow impact of acquisitions and divestments of businesses. (USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Total purchase consideration for acquisitions of businesses -3 807 0 -4 105 0 Acquired cash and cash equivalents 234 236 Contingent consideration payable, net 233 280 -10 Payments (incl. prepayments), deferred consideration and other adjustments, net 47 -100 55 -100 Cash flows used for acquisitions of businesses 1 -3 293 -100 -3 534 -110 Cash flows (used for)/from divestments of businesses, net 2 -26 16 -64 3 Cash flows used for acquisitions and divestments of businesses, net -3 319 -84 -3 598 -107 1 The second quarter and the first half of 2024 include the payments for purchases of MorphoSys shares by Novartis during the Offer period totaling EUR 0.3 billion (USD 0.3 billion), see Note 3 for further information. 2 In the first half of 2024, USD 64 million (Q2 2024: USD 26 million) represented the net cash outflows from divestments in prior years. In the first half of 2023, USD 3 million (Q2 2023: USD 16 million) represented the net cash inflows from divestments from the 2023 periods and prior years. Note 3 provides further information regarding significant acquisitions and divestments of businesses. All acquisitions were for cash.

Legal proceedings update

Legal proceedings update	6 Months Ended
	Jun. 30, 2024
Legal proceedings update [abstract]
Legal proceedings update [text block]	7. Legal proceedings update A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings, including litigations, arbitrations and governmental investigations, that arise from time to time. Legal proceedings are inherently unpredictable. As a result, the Company may become subject to substantial liabilities that may not be covered by insurance and may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 21 to the Consolidated Financial Statements in our 2023 Annual Report and 2023 Form 20-F contains a summary as of the date of these reports of significant legal proceedings to which Novartis or its subsidiaries were a party. The following is a summary as of July 17, 2024, of significant developments in those proceedings, as well as any new significant proceedings commenced since the date of the 2023 Annual Report and 2023 Form 20-F. Investigations and related litigations 340B Drug Pricing Program investigations In 2021, Novartis Pharmaceuticals Corporation (NPC) received a notification from the US Health Resources and Services Administration (HRSA) which stated that HRSA believes NPC’s contract pharmacy policy violates the 340B statute, and threatened potential enforcement action. NPC subsequently sued HRSA in the U.S. District Court (USDC) for the District of Columbia to challenge HRSA’s determination and to enjoin HRSA from taking action with respect to NPC’s contract pharmacy policy. HRSA then referred the matter regarding NPC’s contract pharmacy policy to the Office of Inspector General of the US Department of Health and Human Services, which could result in the imposition of civil monetary penalties on NPC. The USDC issued a decision rejecting HRSA’s interpretation of the 340B statute, vacating the violation notification and remanding the matter to HRSA. HRSA appealed, and the United States Court of Appeals for the DC Circuit heard argument on the case in 2022. In May 2024, the Court of Appeals for the DC Circuit issued a decision rejecting HRSA’s interpretation of the 340B statute and upholding NPC’s current contract pharmacy policy. HRSA has 90 days from the decision to determine whether to seek review from the US Supreme Court or the decision will be final. In addition, NPC has brought litigation challenging a number of state statutes purporting to add further requirements under the 340B program as to the use of contract pharmacies in those states. In addition to the matters described above, there have been other non-material developments in the other legal matters described in Note 21 to the Consolidated Financial Statements contained in our 2023 Annual Report and 2023 Form 20-F. Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.

Operating segments

Operating segments	6 Months Ended
	Jun. 30, 2024
Disclosure of operating segments [abstract]
Operating segment	8. Operating segment Following the September 15, 2023, shareholders’ approval of the spin-off of the Sandoz business, the Company reported its consolidated financial statements for the current and prior years as “continuing operations” and “discontinued operations” (see Note 1 and Note 3). Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business (previously the Innovative Medicines Division) and the continuing corporate activities. Discontinued operations include the Sandoz generic pharmaceuticals and biosimilars business (the Sandoz Division) and certain corporate activities attributable to Sandoz’s business, as well as certain expenses related to the spin-off. Included in fourth quarter of 2023 is also the IFRS Accounting Standards non-cash, non-taxable net gain on the Distribution of Sandoz Group AG to Novartis AG shareholders. For further details and disclosures on discontinued operations, refer to Note 3 and Note 11. The Company’s continuing operations is engaged in the research, development, manufacturing, distribution, and commercialization and sale of innovative medicines, with a focus on the core therapeutic areas: cardiovascular, renal and metabolic; immunology; neuroscience; oncology; and established brands. Following the spin-off of the Sandoz business, on October 3, 2023, Novartis operates as a single global operating segment innovative medicines company that is engaged in the research, development, manufacturing, distribution and commercialization and sale of innovative medicines. The Company’s research, development, manufacturing and supply of products and functional activities are managed globally on a vertically integrated basis. Commercial efforts that coordinate marketing, sales and distribution of these products are organized by geographic region, therapeutic area and established brands. The Executive Committee of Novartis (ECN), chaired by the CEO, is the governance body responsible for allocating resources and assessing the business performance of the operating segment of the Company on a global basis and is the chief operating decision-maker (CODM) for the Company. The determination of a single operating segment is consistent with the financial information regularly reviewed by the CODM for purposes of assessing performance and allocating resources. See Note 9 for revenues and geographic information disclosures.

Revenues and geographic informa

Revenues and geographic information	6 Months Ended
	Jun. 30, 2024
Disclosure of revenues and geographic information [abstract]
Revenues and geographic information	9. Revenues and geographic information Net sales Net sales information Net sales from continuing operations comprise the following: (USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Net sales to third parties from continuing operations 12 512 11 231 24 341 21 776 Sales to discontinued operations 206 459 Net sales from continuing operations 12 512 11 437 24 341 22 235 Net sales from continuing operations by region 1 Second quarter Q2 2024 Q2 2023 % change % change 2 Q2 2024 Q2 2023 US 5 146 4 498 14 14 41 39 Europe 3 867 3 688 5 6 31 32 Asia/Africa/Australasia 2 594 2 425 7 13 21 21 Canada and Latin America 905 826 10 15 7 8 Total 12 512 11 437 9 11 100 100 Of which in established markets 9 162 8 456 8 10 73 74 Of which in emerging growth markets 3 350 2 981 12 16 27 26 1 2 First half H1 2024 H1 2023 % change % change 2 H1 2024 H1 2023 US 9 734 8 548 14 14 40 38 Europe 7 631 7 351 4 5 31 33 Asia/Africa/Australasia 5 174 4 728 9 15 21 21 Canada and Latin America 1 802 1 608 12 15 8 8 Total 24 341 22 235 9 11 100 100 Of which in established markets 17 650 16 351 8 9 73 74 Of which in emerging growth markets 6 691 5 884 14 19 27 26 1 2 Net sales from continuing operations by core therapeutic area and established brands Second quarter Q2 2024 Q2 2023 % change % change USD m USD m 1 USD cc 2 Cardiovascular, renal and metabolic Entresto 1 898 1 516 25 28 Leqvio 182 78 133 134 Total cardiovascular, renal and metabolic 2 080 1 594 30 33 Immunology Cosentyx 1 526 1 272 20 22 Xolair 3 427 362 18 22 Ilaris 368 316 16 20 Other 1 nm nm Total immunology 2 322 1 950 19 22 Neuroscience Kesimpta 799 489 63 65 Zolgensma 349 311 12 14 Aimovig 77 67 15 16 Total neuroscience 1 225 867 41 43 Oncology Kisqali 717 493 45 50 Promacta/Revolade 544 583 -7 -5 Tafinlar Mekinist 523 496 5 9 Jakavi 471 435 8 13 Tasigna 446 476 -6 -4 Pluvicto 345 240 44 44 Lutathera 175 150 17 17 Scemblix 164 106 55 56 Kymriah 113 129 -12 -11 Piqray/Vijoice 120 130 -8 -7 Fabhalta 22 nm nm Total oncology 3 640 3 238 12 15 Total promoted brands 9 267 7 649 21 24 Established brands Sandostatin 313 331 -5 -4 Lucentis 275 395 -30 -28 Exforge 178 184 -3 1 Gilenya 138 269 -49 -47 Diovan 160 155 3 9 Galvus 150 175 -14 -5 Contract manufacturing 271 339 -20 -19 Other 1 760 1 940 -9 -10 Total established brands 3 245 3 788 -14 -13 Total net sales from continuing operations 12 512 11 437 9 11 1 2 3 Xolair nm = not meaningful Net sales from continuing operations by core therapeutic area and established brands First half H1 2024 H1 2023 % change % change USD m USD m 1 USD cc 2 Cardiovascular, renal and metabolic Entresto 3 777 2 915 30 32 Leqvio 333 142 135 137 Total cardiovascular, renal and metabolic 4 110 3 057 34 37 Immunology Cosentyx 2 852 2 348 21 23 Xolair 3 826 716 15 18 Ilaris 724 644 12 17 Other 1 nm nm Total immunology 4 403 3 708 19 21 Neuroscience Kesimpta 1 436 873 64 66 Zolgensma 644 620 4 6 Aimovig 153 128 20 19 Other 1 nm nm Total neuroscience 2 234 1 621 38 39 Oncology Kisqali 1 344 908 48 52 Promacta/Revolade 1 064 1 130 -6 -4 Tafinlar Mekinist 997 954 5 7 Jakavi 949 849 12 15 Tasigna 841 938 -10 -9 Pluvicto 655 451 45 45 Lutathera 344 299 15 16 Scemblix 300 182 65 67 Kymriah 233 264 -12 -10 Piqray/Vijoice 229 246 -7 -6 Fabhalta 28 nm nm Other 1 nm nm Total oncology 6 984 6 222 12 14 Total promoted brands 17 731 14 608 21 23 Established brands Sandostatin 668 660 1 3 Lucentis 589 811 -27 -26 Exforge 370 370 0 3 Gilenya 313 501 -38 -36 Diovan 300 313 -4 1 Galvus 299 358 -16 -9 Contract manufacturing 550 714 -23 -23 Other 3 521 3 900 -10 -10 Total established brands 6 610 7 627 -13 -12 Total net sales from continuing operations 24 341 22 235 9 11 1 2 3 Xolair nm = not meaningful Net sales from continuing operations of the top 20 brands in 2024 Second quarter US Rest of world Total Brands Brand classification by therapeutic area or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular, renal and metabolic Chronic heart failure, hypertension 947 25 951 25 30 1 898 25 28 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS) 868 34 658 6 10 1 526 20 22 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 555 49 244 110 118 799 63 65 Kisqali Oncology HR+/HER2- metastatic breast cancer 375 67 342 27 35 717 45 50 Promacta/Revolade Oncology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 283 -10 261 -3 1 544 -7 -5 Tafinlar Mekinist Oncology BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 202 3 321 7 13 523 5 9 Jakavi Oncology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 471 8 13 471 8 13 Tasigna Oncology Chronic myeloid leukemia (CML) 230 -1 216 -11 -7 446 -6 -4 Xolair 2 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 427 18 22 427 18 22 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 194 19 174 14 22 368 16 20 Sandostatin Established brands Carcinoid tumors, acromegaly 187 -8 126 -2 3 313 -5 -4 Pluvicto Oncology PSMA-positive mCRPC patients post-ARPI, post-Taxane 295 30 50 285 274 345 44 44 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 134 60 215 -5 -3 349 12 14 Lucentis Established brands Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 275 -30 -28 275 -30 -28 Exforge Established brands Hypertension 1 -75 177 -2 2 178 -3 1 Lutathera Oncology GEP-NETs gastroenteropancreatic neuroendocrine tumors 124 17 51 16 19 175 17 17 Leqvio Cardiovascular, renal and metabolic Atherosclerotic cardiovascular disease (ASCVD) 94 114 88 159 165 182 133 134 Gilenya Established brands Relapsing multiple sclerosis (RMS) 30 -71 108 -35 -31 138 -49 -47 Scemblix Oncology Philadelphia chromosome- positive chronic myeloid leukemia (Ph+ CML) 105 35 59 111 112 164 55 56 Diovan Established brands Hypertension 6 -50 154 8 15 160 3 9 Top 20 brands total 4 630 23 5 368 10 14 9 998 15 18 Rest of portfolio 516 -29 1 998 -3 -3 2 514 -10 -10 Total net sales from continuing operations 5 146 14 7 366 6 9 12 512 9 11 1 2 Xolair Net sales from continuing operations of the top 20 brands in 2024 First half US Rest of world Total Brands Brand classification by therapeutic area or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular, renal and metabolic Chronic heart failure, hypertension 1 895 30 1 882 29 34 3 777 30 32 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS) 1 529 30 1 323 13 16 2 852 21 23 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 970 45 466 127 133 1 436 64 66 Kisqali Oncology HR+/HER2- metastatic breast cancer 688 69 656 31 37 1 344 48 52 Promacta/Revolade Oncology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 549 -7 515 -5 -1 1 064 -6 -4 Tafinlar Mekinist Oncology BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 386 -1 611 8 13 997 5 7 Jakavi Oncology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 949 12 15 949 12 15 Tasigna Oncology Chronic myeloid leukemia (CML) 404 -9 437 -12 -9 841 -10 -9 Xolair 2 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 826 15 18 826 15 18 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 360 18 364 7 16 724 12 17 Sandostatin Established brands Carcinoid tumors, acromegaly 426 3 242 -2 2 668 1 3 Pluvicto Oncology PSMA-positive mCRPC patients post-ARPI, post-Taxane 576 33 79 nm nm 655 45 45 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 238 23 406 -5 -3 644 4 6 Lucentis Established brands Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 589 -27 -26 589 -27 -26 Exforge Established brands Hypertension 5 -38 365 1 4 370 0 3 Lutathera Oncology GEP-NETs gastroenteropancreatic neuroendocrine tumors 241 15 103 16 17 344 15 16 Leqvio Cardiovascular, renal and metabolic Atherosclerotic cardiovascular disease (ASCVD) 168 107 165 170 175 333 135 137 Gilenya Established brands Relapsing multiple sclerosis (RMS) 82 -55 231 -27 -25 313 -38 -36 Scemblix Oncology Philadelphia chromosome- positive chronic myeloid leukemia (Ph+ CML) 193 39 107 149 154 300 65 67 Diovan Established brands Hypertension 15 -44 285 0 5 300 -4 1 Top 20 brands total 8 725 22 10 601 12 15 19 326 16 18 Rest of portfolio 1 009 -29 4 006 -4 -3 5 015 -11 -10 Total net sales from continuing operations 9 734 14 14 607 7 10 24 341 9 11 1 2 Xolair nm = not meaningful Other revenues (USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Profit sharing income 268 246 482 445 Royalty income 5 19 24 41 Milestone income 14 25 20 28 Other 1 73 18 125 43 Total other revenues 360 308 651 557 1

Other interim disclosures

Other interim disclosures	6 Months Ended
	Jun. 30, 2024
Disclosure of other interim disclosures [abstract]
Other interim disclosures [text block]	10. Other interim disclosures Property, plant and equipment, right-of-use assets and intangible assets The following table shows additional disclosures related to property, plant and equipment, right-of-use assets and intangible assets for continuing operations: (USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Property, plant and equipment impairment charges -9 -31 -10 -58 Property, plant and equipment impairment reversal 39 48 Property, plant and equipment depreciation charge -219 -222 -437 -455 Right-of-use assets depreciation charge -61 -68 -124 -133 Intangible assets impairment charges 1 -37 -454 -194 -927 Intangible assets amortization charge -836 -974 -1 711 -2 053 1 The first half of 2023 includes an impairment of USD 0.3 billion due to the write-down of IPR&D related to cessation of clinical development program NIZ985. The second quarter and first half of 2023 include an impairment of USD 0.3 billion for the write-down of a currently marketed product to reflect reduction in recoverable amount. In the first half of 2024 and 2023, there were no impairment charges and no reversals of impairment charges on right-of-use assets, as well as no reversals of impairment charges on intangible assets. The following table shows the additions to property, plant and equipment, right-of-use assets and intangible assets for continuing operations excluding the impact of business acquisitions, which are disclosed in Note 3: (USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Additions to property, plant and equipment 283 211 506 388 Additions to right-of-use assets 69 49 97 192 Additions to intangible assets other than goodwill 512 521 1 175 716 Financial debt Novartis issued the following straight bonds during the second quarter of 2024: Carrying value 1.600% CHF 650 2027 Novartis AG, Basel, Switzerland 100.138% 723 1.650% CHF 435 2031 Novartis AG, Basel, Switzerland 100.148% 483 1.750% CHF 645 2034 Novartis AG, Basel, Switzerland 100.229% 717 1.850% CHF 280 2040 Novartis AG, Basel, Switzerland 100.268% 311 1.850% CHF 190 2049 Novartis AG, Basel, Switzerland 100.149% 211 In the second quarter of 2024, Novartis repaid the 3.4% In May 2024, Novartis replaced its existing USD 6.0 billion credit facility with a syndicate of banks (which was undrawn at its replacement date and December 31, 2023 and had a maturity date of September 2025) with a new USD 6.0 billion credit facility with a syndicate of banks. This credit facility is intended to be used as a backstop for the US commercial paper program. This facility matures in May 2029, and was undrawn as at June 30, 2024. Research and development commitments The Company has entered into long-term research and development agreements with various institutions related to intangible assets. These agreements provide for potential milestone payments by Novartis, which are dependent on successful clinical development, or meeting specified sales targets, or other conditions that are specified in the agreements. As of June 30, 2024, the amount and estimated timing of the Company’s commitments to make payments under those agreements, which are shown without risk adjustment and on an undiscounted basis, were as follows: (USD millions) 2024 2024 226 2025 209 2026 460 2027 396 2028 566 2029 487 Thereafter 4 855 Total 7 199 Significant pending transaction In July 2024, Novartis entered into a long-term research and development agreement which did not close as of July 17, 2024. This agreement provides for potential milestones payments by Novartis that may be capitalized and royalties. Based on their estimated timing, the payments for this transaction are expected to amount to USD 0.1 billion in 2024, USD 0.1 billion in 2026, USD 0.1 billion in 2028, USD 0.1 billion in 2029 and USD 1.0 billion thereafter.

Discontinued operations

Discontinued operations	6 Months Ended
	Jun. 30, 2024
Disclosure of discontinued operations [abstract]
Discontinued operations	11. Discontinued operations Discontinued operations included the operational results from the Sandoz generic pharmaceuticals and biosimilars division and certain corporate activities attributable to the Sandoz business, as well as certain other expenses related to the spin-off (refer to Note 3 for further details). The Sandoz business operated in the off-patent medicines segment and specialized in the development, manufacturing, and marketing of generic pharmaceuticals and biosimilars. The Sandoz business was organized globally into two franchises: Generics and Biosimilars. As the Sandoz business spin-off was completed on October 3, 2023, there were no operating results in the first half of 2024. Net income from discontinued operations (USD millions unless indicated otherwise) Q2 2023 H1 2023 Net sales to third parties from discontinued operations 2 391 4 799 Sales to continuing operations 58 153 Net sales from discontinued operations 2 449 4 952 Other revenues 6 12 Cost from goods sold -1 263 -2 551 Gross profit from discontinued operations 1 192 2 413 Selling, general and administration -595 -1 147 Research and development -222 -441 Other income 21 28 Other expense -283 -502 Operating income from discontinued operations 113 351 Income from associated companies 1 Interest expense -8 -19 Other financial income and expense -10 -18 Income before taxes from discontinued operations 95 315 Income taxes 1 -49 -125 Net income from discontinued operations 46 190 1 The tax rate in the second quarter of 2023 and in the first half of 2023 was impacted by non-recurring items such as net increases in uncertain tax positions of the Sandoz business and non-deductible expenses recognized related to a legal matter. Excluding these impacts, the tax rate would have been 31.5% in the second quarter of 2023 and 28.6% in the first half of 2023. Supplemental disclosures related to discontinued operations Net income from discontinued operations Included in net income from discontinued operations were: (USD millions unless indicated otherwise) Q2 2023 H1 2023 Interest income 1 Depreciation of property, plant and equipment -48 -99 Depreciation of right-of-use assets -10 -18 Amortization of intangible assets -56 -111 Impairment charges on property, plant and equipment -1 -2 Impairment charges on intangible assets -1 -13 Impairment reversals of property, plant and equipment 1 1 Additions to restructuring provisions -11 -16 Equity-based compensation expense related to Novartis equity-based participation plans -18 -36 In 2023 there were no impairment charges and no reversals of impairment charges on right-of-use assets and no reversals of impairment charges on intangible assets of discontinued operations. Other information The following table shows for discontinued operations the additions to property, plant and equipment, right-of-use assets and intangible assets: (USD millions) Q2 2023 H1 2023 Additions to property, plant and equipment 82 160 Additions to right-of-use assets 24 33 Additions to goodwill and intangible assets 35 56 For additional information related to the October 3, 2023 distribution (spin-off) of the Sandoz business to Novartis AG shareholders, effected through a dividend in kind distribution of Sandoz Group AG shares to Novartis AG shareholders and ADR holders, refer to Note 3.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2024
Disclosure of non-adjusting events after reporting period [abstract]
Events subsequent to the June 30, consolidated balance sheet date	12. Events subsequent to the June 30, 2024, consolidated balance sheet Significant pending transaction On July 4, 2024, Novartis filed a public delisting purchase offer to delist the MorphoSys shares admitted to trading on regulated markets and acquire all MorphoSys AG shares and ADS not held directly by Novartis. For disclosure of the MorphoSys business acquisition, see Note 3. In July 2024, Novartis entered into a long-term research and development agreement, which did not close as of July 17, 2024. See Note 10 for further information.

Accounting policies (Policies)

Accounting policies (Policies)	6 Months Ended
	Jun. 30, 2024
Significant Accounting Policies [abstract]
Disclosure of changes in accounting policies, accounting estimates and errors [text block]	The Company’s accounting policies are set out in Note 1 to the Consolidated Financial Statements in the 2023 Annual Report and conform with IFRS Accounting Standards as issued by the International Accounting Standards Board. The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, which affect the reported amounts of revenues, expenses, assets, liabilities and contingent amounts. Estimates are based on historical experience and other assumptions that are considered reasonable under the given circumstances and are regularly monitored. Actual outcomes and results could differ from those estimates and assumptions. Revisions to estimates are recognized in the period in which the estimate is revised. As disclosed in the 2023 Annual Report, goodwill, and acquired In-Process Research & Development projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value. The amount of goodwill and other intangible assets on the Company’s consolidated balance sheet has risen significantly in recent years, primarily from acquisitions. Impairment testing may lead to potentially significant impairment charges in the future that could have a materially adverse impact on the Company’s results of operations and financial condition. The Company’s activities are not subject to significant seasonal fluctuations. Status of adoption of significant new or amended IFRS standards or interpretations No new IFRS Accounting Standards were adopted by the Company in 2024. In addition, new IFRS Accounting Standards amendments or interpretations that became effective in 2024 did not have a material impact on the Company’s consolidated financial statements. Based on the Company’s assessment, there are no IFRS Accounting Standards, amendments or interpretations not yet effective in 2024 that would be expected to have a material impact on the Company’s consolidated financial statements. In the second quarter of 2024, the following new IFRS Accounting Standard, which is not yet effective, was issued by the International Accounting Standards Board: IFRS 18 Presentation and Disclosures in Financial Statements IFRS 18 Presentation and Disclosure in Financial Statements was issued by the International Accounting Standards Board in April 2024. IFRS 18 is effective on January 1, 2027, and is required to be applied retrospectively to comparative periods presented, with early adoption permitted. IFRS 18, upon adoption replaces IAS Standards 1 - Presentation of Financial Statements. IFRS 18 sets out new requirements focused on improving financial reporting by: • requiring additional defined structure to the statement of profit or loss (i.e. consolidated statement of income), to reduce diversity in the reporting, by requiring five categories (operating, investing, financing, income taxes and discontinued operations) and defined subtotals and totals (operating income, income before financing, income taxes and net income), • requiring disclosures in the notes to the financial statements about management-defined performance measures (i.e. non-IFRS measures), and • adding new principles for aggregation and disaggregation of information in the primary financial statements and notes. IFRS 18 will not impact the recognition or measurement of items in the financial statements, but it might change what an entity reports as its ‘operating profit or loss’, due to the classification of certain income and expense items between the five categories of the consolidated income statement. It might also change what an entity reports as operating activities, investing activities and financing activities within the statement of cash flows, due to the change in classification of certain cash flow items between these three categories of the cash flows statement. Novartis is currently assessing the impact of adopting IFRS 18.

Significant acquisition of bu_2

Significant acquisition of businesses (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of significant transactions [abstract]
Net gain at completion of spin-off	Oct 3, Net assets derecognized -8 647 Derecognition of distribution liability 13 962 Difference between net assets and distribution liability 5 315 Recognition of Sandoz Group AG shares Currency translation gains recycled into Transaction costs and other items recognized in the consolidated income statement -304 Gain on distribution of Sandoz Group AG to Novartis AG shareholders 5 860
Fair value of assets and liabilities arising from acquisitions	Jun 30, Dec 31, Property, plant and equipment 23 18 Right-of-use assets 32 16 In-process research and development 1 746 2 931 Other intangible assets 1 419 15 Deferred tax assets 315 34 Non-current financial and other assets 421 164 Trade receivable and financial and Cash and cash equivalents 236 226 Deferred tax liabilities -600 -474 Current and non-current financial debts -905 Current and non-current lease liabilities -41 -51 Trade payables and other liabilities -289 -231 Net identifiable assets acquired 2 015 2 831 Non-controlling interests -108 Goodwill 2 198 1 094 Total purchase consideration for acquisitions of businesses 4 105 3 925 1

Summary of equity attributabl_2

Summary of equity attributable to Novartis AG shareholders (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of equity [abstract]
Summary of treasury shares movements [table text block]	Number of outstanding shares (in millions) Issued share capital and reserves attributable to Novartis AG shareholders (in USD millions) Note 2024 2023 H1 2024 H1 2023 Balance at beginning of year 2 044.0 2 119.6 46 667 59 342 Shares acquired to be canceled -26.7 -61.3 -2 698 -5 767 Other share purchases -1.1 -1.3 -115 -121 Exercise of options and employee transactions 0.0 2.8 -35 153 Equity-based compensation 8.3 8.5 552 433 Shares delivered to Sandoz employees as a result of the Sandoz spin-off 0.1 12 Taxes on treasury share transactions 8 8 Dividends 4.1 -7 624 -7 255 Net income of the period attributable to shareholders of Novartis AG 5 934 4 609 Other comprehensive income attributable to shareholders of Novartis AG -1 054 387 Impact of change in ownership of consolidated entities -28 Other movements 4.3 114 58 Balance at June 30 2 024.6 2 068.3 41 733 51 847

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Jun. 30, 2024
Financial Instruments - additional disclosure [abstract]
Disclosure of fair value measurement [text block]	Level 1 Level 2 Level 3 Total Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Jun 30, Dec 31, Financial assets Cash and cash equivalents Debt securities 50 50 50 50 Total cash and cash equivalents at fair value 50 50 50 50 Marketable securities Fund investments 405 405 Derivative financial instruments 60 355 60 355 Total marketable securities and derivative financial instruments at fair value 405 60 355 465 355 Current contingent consideration receivables 90 65 90 65 Current fund investments and equity securities 34 94 22 31 56 125 Long-term financial investments Debt and equity securities 275 796 7 20 642 616 924 1 432 Fund investments 12 7 191 183 203 190 Non-current contingent consideration receivables 501 553 501 553 Total long-term financial investments at fair value 287 803 7 20 1 334 1 352 1 628 2 175 Associated companies at fair value through profit or loss 101 101 101 101 Financial liabilities Current contingent consideration liabilities -154 -14 -154 -14 Current other financial liabilities -88 -88 Derivative financial instruments -54 -91 -54 -91 Total current financial liabilities at fair value -54 -91 -154 -102 -208 -193 Non-current contingent consideration liabilities -546 -389 -546 -389

Details to the consolidated s_2

Details to the consolidated statements of cash flows (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of details to the consolidated statements of cash flows [abstract]
Adjustments for non-cash items from continuing operations	(USD millions) Q2 2024 Q2 2023 Depreciation, amortization and impairments on: Property, plant and equipment 228 213 Right-of-use assets 61 68 Intangible assets 873 1 427 Financial assets 1 -22 29 Change in provisions and other non-current liabilities 204 -53 Losses on disposal on property, plant and equipment; intangible assets; other non-current assets; Equity-settled compensation expense 257 222 Loss from associated companies 2 2 Income taxes 595 403 Net financial expense 171 131 Other -41 39 Total 2 400 2 567 1 (USD millions) H1 2024 H1 2023 Depreciation, amortization and impairments on: Property, plant and equipment 447 465 Right-of-use assets 124 133 Intangible assets 1 905 2 980 Financial assets 1 6 75 Change in provisions and other non-current liabilities 367 362 Losses/(gains) on disposal on property, plant and equipment; intangible assets; other non-current assets; -216 Equity-settled compensation expense 517 412 Loss from associated companies 31 4 Income taxes 1 036 773 Net financial expense 386 227 Other -64 34 Total 4 897 5 249 1
Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations	(USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Increase in inventories -18 -185 -146 -546 Increase in trade receivables -501 -447 -1 421 -1 147 (Decrease)/increase in trade payables -142 73 -551 99 Change in other current and non-current assets -105 9 -377 -100 Change in other current liabilities 1 004 605 744 531 Total 238 55 -1 751 -1 163
Cash flows arising from acquisitions and divestments of businesses	(USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Total purchase consideration for acquisitions of businesses -3 807 0 -4 105 0 Acquired cash and cash equivalents 234 236 Contingent consideration payable, net 233 280 -10 Payments (incl. prepayments), deferred consideration and other adjustments, net 47 -100 55 -100 Cash flows used for acquisitions of businesses 1 -3 293 -100 -3 534 -110 Cash flows (used for)/from divestments of businesses, net 2 -26 16 -64 3 Cash flows used for acquisitions and divestments of businesses, net -3 319 -84 -3 598 -107 1 The second quarter and the first half of 2024 include the payments for purchases of MorphoSys shares by Novartis during the Offer period totaling EUR 0.3 billion (USD 0.3 billion), see Note 3 for further information. 2 In the first half of 2024, USD 64 million (Q2 2024: USD 26 million) represented the net cash outflows from divestments in prior years. In the first half of 2023, USD 3 million (Q2 2023: USD 16 million) represented the net cash inflows from divestments from the 2023 periods and prior years.

Revenues and geographic infor_2

Revenues and geographic information (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of operating segments [abstract]
Net sales from continuing operations	(USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Net sales to third parties from continuing operations 12 512 11 231 24 341 21 776 Sales to discontinued operations 206 459 Net sales from continuing operations 12 512 11 437 24 341 22 235
Net sales by region	Net sales from continuing operations by region 1 Second quarter Q2 2024 Q2 2023 % change % change 2 Q2 2024 Q2 2023 US 5 146 4 498 14 14 41 39 Europe 3 867 3 688 5 6 31 32 Asia/Africa/Australasia 2 594 2 425 7 13 21 21 Canada and Latin America 905 826 10 15 7 8 Total 12 512 11 437 9 11 100 100 Of which in established markets 9 162 8 456 8 10 73 74 Of which in emerging growth markets 3 350 2 981 12 16 27 26 1 2 First half H1 2024 H1 2023 % change % change 2 H1 2024 H1 2023 US 9 734 8 548 14 14 40 38 Europe 7 631 7 351 4 5 31 33 Asia/Africa/Australasia 5 174 4 728 9 15 21 21 Canada and Latin America 1 802 1 608 12 15 8 8 Total 24 341 22 235 9 11 100 100 Of which in established markets 17 650 16 351 8 9 73 74 Of which in emerging growth markets 6 691 5 884 14 19 27 26 1 2
Net sales by core therapeutic area and established brands	Net sales from continuing operations by core therapeutic area and established brands Second quarter Q2 2024 Q2 2023 % change % change USD m USD m 1 USD cc 2 Cardiovascular, renal and metabolic Entresto 1 898 1 516 25 28 Leqvio 182 78 133 134 Total cardiovascular, renal and metabolic 2 080 1 594 30 33 Immunology Cosentyx 1 526 1 272 20 22 Xolair 3 427 362 18 22 Ilaris 368 316 16 20 Other 1 nm nm Total immunology 2 322 1 950 19 22 Neuroscience Kesimpta 799 489 63 65 Zolgensma 349 311 12 14 Aimovig 77 67 15 16 Total neuroscience 1 225 867 41 43 Oncology Kisqali 717 493 45 50 Promacta/Revolade 544 583 -7 -5 Tafinlar Mekinist 523 496 5 9 Jakavi 471 435 8 13 Tasigna 446 476 -6 -4 Pluvicto 345 240 44 44 Lutathera 175 150 17 17 Scemblix 164 106 55 56 Kymriah 113 129 -12 -11 Piqray/Vijoice 120 130 -8 -7 Fabhalta 22 nm nm Total oncology 3 640 3 238 12 15 Total promoted brands 9 267 7 649 21 24 Established brands Sandostatin 313 331 -5 -4 Lucentis 275 395 -30 -28 Exforge 178 184 -3 1 Gilenya 138 269 -49 -47 Diovan 160 155 3 9 Galvus 150 175 -14 -5 Contract manufacturing 271 339 -20 -19 Other 1 760 1 940 -9 -10 Total established brands 3 245 3 788 -14 -13 Total net sales from continuing operations 12 512 11 437 9 11 1 2 3 Xolair nm = not meaningful Net sales from continuing operations by core therapeutic area and established brands First half H1 2024 H1 2023 % change % change USD m USD m 1 USD cc 2 Cardiovascular, renal and metabolic Entresto 3 777 2 915 30 32 Leqvio 333 142 135 137 Total cardiovascular, renal and metabolic 4 110 3 057 34 37 Immunology Cosentyx 2 852 2 348 21 23 Xolair 3 826 716 15 18 Ilaris 724 644 12 17 Other 1 nm nm Total immunology 4 403 3 708 19 21 Neuroscience Kesimpta 1 436 873 64 66 Zolgensma 644 620 4 6 Aimovig 153 128 20 19 Other 1 nm nm Total neuroscience 2 234 1 621 38 39 Oncology Kisqali 1 344 908 48 52 Promacta/Revolade 1 064 1 130 -6 -4 Tafinlar Mekinist 997 954 5 7 Jakavi 949 849 12 15 Tasigna 841 938 -10 -9 Pluvicto 655 451 45 45 Lutathera 344 299 15 16 Scemblix 300 182 65 67 Kymriah 233 264 -12 -10 Piqray/Vijoice 229 246 -7 -6 Fabhalta 28 nm nm Other 1 nm nm Total oncology 6 984 6 222 12 14 Total promoted brands 17 731 14 608 21 23 Established brands Sandostatin 668 660 1 3 Lucentis 589 811 -27 -26 Exforge 370 370 0 3 Gilenya 313 501 -38 -36 Diovan 300 313 -4 1 Galvus 299 358 -16 -9 Contract manufacturing 550 714 -23 -23 Other 3 521 3 900 -10 -10 Total established brands 6 610 7 627 -13 -12 Total net sales from continuing operations 24 341 22 235 9 11 1 2 3 Xolair nm = not meaningful
Net sales of Top 20 products	Net sales from continuing operations of the top 20 brands in 2024 Second quarter US Rest of world Total Brands Brand classification by therapeutic area or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular, renal and metabolic Chronic heart failure, hypertension 947 25 951 25 30 1 898 25 28 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS) 868 34 658 6 10 1 526 20 22 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 555 49 244 110 118 799 63 65 Kisqali Oncology HR+/HER2- metastatic breast cancer 375 67 342 27 35 717 45 50 Promacta/Revolade Oncology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 283 -10 261 -3 1 544 -7 -5 Tafinlar Mekinist Oncology BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 202 3 321 7 13 523 5 9 Jakavi Oncology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 471 8 13 471 8 13 Tasigna Oncology Chronic myeloid leukemia (CML) 230 -1 216 -11 -7 446 -6 -4 Xolair 2 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 427 18 22 427 18 22 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 194 19 174 14 22 368 16 20 Sandostatin Established brands Carcinoid tumors, acromegaly 187 -8 126 -2 3 313 -5 -4 Pluvicto Oncology PSMA-positive mCRPC patients post-ARPI, post-Taxane 295 30 50 285 274 345 44 44 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 134 60 215 -5 -3 349 12 14 Lucentis Established brands Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 275 -30 -28 275 -30 -28 Exforge Established brands Hypertension 1 -75 177 -2 2 178 -3 1 Lutathera Oncology GEP-NETs gastroenteropancreatic neuroendocrine tumors 124 17 51 16 19 175 17 17 Leqvio Cardiovascular, renal and metabolic Atherosclerotic cardiovascular disease (ASCVD) 94 114 88 159 165 182 133 134 Gilenya Established brands Relapsing multiple sclerosis (RMS) 30 -71 108 -35 -31 138 -49 -47 Scemblix Oncology Philadelphia chromosome- positive chronic myeloid leukemia (Ph+ CML) 105 35 59 111 112 164 55 56 Diovan Established brands Hypertension 6 -50 154 8 15 160 3 9 Top 20 brands total 4 630 23 5 368 10 14 9 998 15 18 Rest of portfolio 516 -29 1 998 -3 -3 2 514 -10 -10 Total net sales from continuing operations 5 146 14 7 366 6 9 12 512 9 11 1 2 Xolair Net sales from continuing operations of the top 20 brands in 2024 First half US Rest of world Total Brands Brand classification by therapeutic area or established brands Key indications USD m % change USD/cc 1 USD m % change USD % change cc 1 USD m % change USD % change cc 1 Entresto Cardiovascular, renal and metabolic Chronic heart failure, hypertension 1 895 30 1 882 29 34 3 777 30 32 Cosentyx Immunology Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS) 1 529 30 1 323 13 16 2 852 21 23 Kesimpta Neuroscience Relapsing-remitting multiple sclerosis (RRMS) 970 45 466 127 133 1 436 64 66 Kisqali Oncology HR+/HER2- metastatic breast cancer 688 69 656 31 37 1 344 48 52 Promacta/Revolade Oncology Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) 549 -7 515 -5 -1 1 064 -6 -4 Tafinlar Mekinist Oncology BRAF V600+ metastatic adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication 386 -1 611 8 13 997 5 7 Jakavi Oncology Myelofibrosis (MF), polycytomia vera (PV), graft-versus-host disease (GvHD) 949 12 15 949 12 15 Tasigna Oncology Chronic myeloid leukemia (CML) 404 -9 437 -12 -9 841 -10 -9 Xolair 2 Immunology Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps 826 15 18 826 15 18 Ilaris Immunology Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout) 360 18 364 7 16 724 12 17 Sandostatin Established brands Carcinoid tumors, acromegaly 426 3 242 -2 2 668 1 3 Pluvicto Oncology PSMA-positive mCRPC patients post-ARPI, post-Taxane 576 33 79 nm nm 655 45 45 Zolgensma Neuroscience Spinal muscular atrophy (SMA) 238 23 406 -5 -3 644 4 6 Lucentis Established brands Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) 589 -27 -26 589 -27 -26 Exforge Established brands Hypertension 5 -38 365 1 4 370 0 3 Lutathera Oncology GEP-NETs gastroenteropancreatic neuroendocrine tumors 241 15 103 16 17 344 15 16 Leqvio Cardiovascular, renal and metabolic Atherosclerotic cardiovascular disease (ASCVD) 168 107 165 170 175 333 135 137 Gilenya Established brands Relapsing multiple sclerosis (RMS) 82 -55 231 -27 -25 313 -38 -36 Scemblix Oncology Philadelphia chromosome- positive chronic myeloid leukemia (Ph+ CML) 193 39 107 149 154 300 65 67 Diovan Established brands Hypertension 15 -44 285 0 5 300 -4 1 Top 20 brands total 8 725 22 10 601 12 15 19 326 16 18 Rest of portfolio 1 009 -29 4 006 -4 -3 5 015 -11 -10 Total net sales from continuing operations 9 734 14 14 607 7 10 24 341 9 11 1 2 Xolair nm = not meaningful
Other revenue	(USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Profit sharing income 268 246 482 445 Royalty income 5 19 24 41 Milestone income 14 25 20 28 Other 1 73 18 125 43 Total other revenues 360 308 651 557 1

Other interim disclosures (Tabl

Other interim disclosures (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of other interim disclosures [abstract]
Disclosure of impairment loss and reversal of impairment loss [text block]	(USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Property, plant and equipment impairment charges -9 -31 -10 -58 Property, plant and equipment impairment reversal 39 48 Property, plant and equipment depreciation charge -219 -222 -437 -455 Right-of-use assets depreciation charge -61 -68 -124 -133 Intangible assets impairment charges 1 -37 -454 -194 -927 Intangible assets amortization charge -836 -974 -1 711 -2 053 1 The first half of 2023 includes an impairment of USD 0.3 billion due to the write-down of IPR&D related to cessation of clinical development program NIZ985. The second quarter and first half of 2023 include an impairment of USD 0.3 billion for the write-down of a currently marketed product to reflect reduction in recoverable amount.
Disclosure of additions excluding the impact of business acquisitions [table text block]	(USD millions) Q2 2024 Q2 2023 H1 2024 H1 2023 Additions to property, plant and equipment 283 211 506 388 Additions to right-of-use assets 69 49 97 192 Additions to intangible assets other than goodwill 512 521 1 175 716
Disclosure of detailed information about borrowings [table text block]	Carrying value 1.600% CHF 650 2027 Novartis AG, Basel, Switzerland 100.138% 723 1.650% CHF 435 2031 Novartis AG, Basel, Switzerland 100.148% 483 1.750% CHF 645 2034 Novartis AG, Basel, Switzerland 100.229% 717 1.850% CHF 280 2040 Novartis AG, Basel, Switzerland 100.268% 311 1.850% CHF 190 2049 Novartis AG, Basel, Switzerland 100.149% 211
Disclosure of Leasing commitments [table text block]	(USD millions) 2024 2024 226 2025 209 2026 460 2027 396 2028 566 2029 487 Thereafter 4 855 Total 7 199

Discontinued operations (Tables

Discontinued operations (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure of discontinued operations [abstract]
Net income from discontinued operations	(USD millions unless indicated otherwise) Q2 2023 H1 2023 Net sales to third parties from discontinued operations 2 391 4 799 Sales to continuing operations 58 153 Net sales from discontinued operations 2 449 4 952 Other revenues 6 12 Cost from goods sold -1 263 -2 551 Gross profit from discontinued operations 1 192 2 413 Selling, general and administration -595 -1 147 Research and development -222 -441 Other income 21 28 Other expense -283 -502 Operating income from discontinued operations 113 351 Income from associated companies 1 Interest expense -8 -19 Other financial income and expense -10 -18 Income before taxes from discontinued operations 95 315 Income taxes 1 -49 -125 Net income from discontinued operations 46 190 1 The tax rate in the second quarter of 2023 and in the first half of 2023 was impacted by non-recurring items such as net increases in uncertain tax positions of the Sandoz business and non-deductible expenses recognized related to a legal matter. Excluding these impacts, the tax rate would have been 31.5% in the second quarter of 2023 and 28.6% in the first half of 2023.
Items included in net income from discontinued operations	(USD millions unless indicated otherwise) Q2 2023 H1 2023 Interest income 1 Depreciation of property, plant and equipment -48 -99 Depreciation of right-of-use assets -10 -18 Amortization of intangible assets -56 -111 Impairment charges on property, plant and equipment -1 -2 Impairment charges on intangible assets -1 -13 Impairment reversals of property, plant and equipment 1 1 Additions to restructuring provisions -11 -16 Equity-based compensation expense related to Novartis equity-based participation plans -18 -36
Additions to property, plant and equipment, right-of-use assets and goodwill and intangible assets for discontinued operations	(USD millions) Q2 2023 H1 2023 Additions to property, plant and equipment 82 160 Additions to right-of-use assets 24 33 Additions to goodwill and intangible assets 35 56

Significant acquisition of bu_3

Significant acquisition of businesses (Details) $ in Millions								1 Months Ended			3 Months Ended		6 Months Ended
	May 30, 2024 USD ($)	May 23, 2024 USD ($)	May 23, 2024 EUR (€)	May 02, 2024 USD ($)	Oct. 03, 2023 USD ($)	Aug. 11, 2023 USD ($)	Jul. 14, 2023 USD ($)	Jun. 30, 2024 USD ($)	May 23, 2024 USD ($)	May 23, 2024 EUR (€)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 EUR (€)	May 30, 2024 EUR (€)	Apr. 11, 2024 EUR (€)	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 18, 2023 USD ($)	Sep. 18, 2023 EUR (€)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Disclosure of detailed information about business combination [line items]
Identifiable assets acquired (liabilities assumed)								$ 4,105			$ 4,105		$ 4,105						$ 3,925
Profit (loss) from discontinued operations												$ 46		$ 190
Intangible assets other than goodwill								27,775			27,775		27,775						26,879
Revenue from sale of goods											12,512	11,437	24,341	22,235
Dividend in kind distribution liability					$ 13,962
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed					5,315
Difference between carrying amount of dividends payable and carrying amount of non-cash assets distributed, Net					$ 5,860
Non-controlling interests								169			169		169						83
Other current financial assets								532			532		532						1,035
Cash and cash equivalents								7,903			7,903	10,885	7,903	10,885				$ 9,469	$ 13,393			$ 12,000	$ 7,517
Sandoz
Disclosure of detailed information about business combination [line items]
Detailed information about significant transaction					The conditions precedent to the spin-off were met and on October 3, 2023 the spin-off of the Sandoz business was effected by way of a distribution of a dividend in kind of Sandoz Group AG shares to Novartis AG shareholders and American Depositary Receipt (ADR) holders (the Distribution). Through the Distribution, each Novartis AG shareholder received 1 Sandoz Group AG share for every 5 Novartis AG shares and each Novartis ADR holder received 1 Sandoz ADR for every 5 Novartis ADR that they held at the close of business on October 3, 2023. As of October 4, 2023, the shares of Sandoz Group AG have been listed on the SIX Swiss Exchange (SIX) under the stock symbol “SDZ”.
Chinook Therapeutics
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value						$ 3,300
Portion of consideration paid (received) consisting of cash and cash equivalents						(100)
Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment						3,200
Identifiable assets acquired (liabilities assumed)						2,400
Additional recognition, goodwill						900
Other net assets						300
Potential milestone maximum payments						300
Contingent consideration recognised as of acquisition date						100
Chinook Therapeutics | Acquired research and development [member]
Disclosure of detailed information about business combination [line items]
Intangible assets other than goodwill						2,500
DTx Pharma Inc.
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value							$ 600
Portion of consideration paid (received) consisting of cash and cash equivalents							(100)
Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment							600
Identifiable assets acquired (liabilities assumed)							400
Additional recognition, goodwill							200
Deferred tax liability (asset)						$ 400	100
Potential milestone maximum payments							500
Cash transferred							600
Contingent consideration recognised as of acquisition date							30
DTx Pharma Inc. | Acquired research and development [member]
Disclosure of detailed information about business combination [line items]
Intangible assets other than goodwill							$ 400
Mariana Oncology
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value				$ 1,300
Portion of consideration paid (received) consisting of cash and cash equivalents				(100)
Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment				1,100
Identifiable assets acquired (liabilities assumed)				700
Additional recognition, goodwill				600
Deferred tax liability (asset)				100
Potential milestone maximum payments				800
Contingent consideration recognised as of acquisition date				200
Mariana Oncology | Acquired research and development [member]
Disclosure of detailed information about business combination [line items]
Intangible assets other than goodwill				300
Mariana Oncology | Other intangible assets [member]
Disclosure of detailed information about business combination [line items]
Intangible assets other than goodwill				$ 400
MorphoSys AG
Disclosure of detailed information about business combination [line items]
Consideration transferred, acquisition-date fair value	$ 2,500							2,500			2,500		2,500			€ 2,300,000,000	€ 2,600,000,000
Portion of consideration paid (received) consisting of cash and cash equivalents								(200)
Portion of consideration paid (received) consisting of cash and cash equivalents upfront payment		$ 1,900	€ 1,700,000,000						$ 300	€ 300,000,000
Identifiable assets acquired (liabilities assumed)								1,000			$ 1,000		$ 1,000
Additional recognition, goodwill								$ 1,600
Percentage of Share capital in tender offer																	65%
Cash offer per ordinary share | €																	€ 68
Percentage of share capital owned								91.40%			91.40%		91.40%		91.40%
Deferred tax liability (asset)								$ 100			$ 100		$ 100
Consideration paid for share capital tendered at the subsequent offering period of the tender offer	$ 300															€ 300,000,000
Percentage of share capital tendered after the expiration of the tender offer	89.70%															89.70%
Percentage of share capital purchased by the company outside the tender offer								1.70%			1.70%		1.70%		1.70%
Proportion of ownership interests held by non-controlling interests	10.30%							8.60%
Non-controlling interests	$ 100							$ 100			$ 100		$ 100
Reduction of non-controlling interests								17			17		17
Financial investments and other receivable								600			600		600
Other current financial assets								400			400		400
Financial debt to third parties								900			900		900
Other net liabilities								200			200		200
Purchase of non-controlling interests								47			47		47		€ 44,000,000
MorphoSys AG | Acquired research and development [member]
Disclosure of detailed information about business combination [line items]
Intangible assets other than goodwill								$ 1,100			$ 1,100		$ 1,100
Discontinued operations
Disclosure of detailed information about business combination [line items]
Profit (loss) from discontinued operations												46		190
Revenue from sale of goods												2,449		4,952
Depreciation, property, plant and equipment												48		99
Amortisation, intangible assets other than goodwill												56		111
Impairment loss recognised in profit or loss, intangible assets and goodwill												$ (1)		$ (13)
Discontinued operations | Sandoz
Disclosure of detailed information about business combination [line items]
Repayment of intercompany balances					$ (3,300)
Other borrowings																				$ 3,300
Dividend in kind distribution liability					14,000
Borrowings					3,700
Financial assets, at fair value					$ 500
Percentage of equity interest shares received					4.31%
Discontinued operations | Sandoz | Bridge loan [member]
Disclosure of detailed information about business combination [line items]
Other borrowings | €																					€ 2,400,000,000
Discontinued operations | Sandoz | Term loan [member]
Disclosure of detailed information about business combination [line items]
Other borrowings																				500	€ 200,000,000
Discontinued operations | Sandoz | Local bilateral facilities [member]
Disclosure of detailed information about business combination [line items]
Other borrowings																				$ 400

Significant acquisition of bu_4

Significant acquisition of businesses (Details 2) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]
Property, plant and equipment recognised as of acquisition date	$ 23	$ 18
Right of use assets as of acquisition date	32	16
Acquired research and development	1,746	2,931
Other intangible assets recognised as of acquisition date	419	15
Deferred tax assets	315	34
Non-current financial and other assets	421	164
Trade receivables and other current assets recognised as of acquisition date	658	183
Cash and cash equivalents	236	226
Deferred tax liabilities recognised as of acquisition date	(600)	(474)
Current and non current financial debts as of acquisition date	(905)
Current and non current lease liabilities as of acquisition date	(41)	(51)
Trade payables and other liabilities	(289)	(231)
Net identifiable assets acquired	2,015	2,831
Non-controlling interests	(108)
Goodwill	2,198	1,094
Identifiable assets acquired (liabilities assumed)	$ 4,105	$ 3,925

Significant acquisition of bu_5

Significant acquisition of businesses (Details 3) $ in Millions	Oct. 03, 2023 USD ($)
Disclosure of detailed information about business combination [line items]
Net assets derecognized	$ (8,647)
Derecognition of distribution liability	13,962
Difference between net assets and distribution liability	5,315
Distribution of dividend to dividend bearing shares	492
Cumulative currency translation gains/losses recycled through income statement	357
Transaction costs recognized in the consolidated income statement	(304)
Gain on distribution of Sandoz Group AG to Novartis AG shareholders	$ 5,860

Summary of equity attributabl_3

Summary of equity attributable to Novartis AG shareholders (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of classes of share capital [line items]
Equity at beginning of period	$ 39,756	$ 52,142	$ 46,750	$ 59,423
Exercise of options and employee transactions, equity impact	(1)		(35)	153
Equity-based compensation, equity impact	268	242	552	433
Shares delivered to divested business employees, equity impact Sandoz	2		12
Taxes on treasury shares	12		(8)	(8)
Dividends			(7,624)	(7,255)
Net income	3,246	2,317	5,934	4,611
Other comprehensive income	205	219	(1,058)	$ 388
Net dividend paid			5,200
Withholding tax on the gross dividend			$ 2,400
Equity attributable to owners of parent [member]
Disclosure of classes of share capital [line items]
Number of shares outstanding at beginning of period			2,044	2,119.6
Equity at beginning of period	39,675	52,059	$ 46,667	$ 59,342
Shares acquired to be cancelled			(26.7)	(61.3)
Shares acquired for cancellation, equity impact			$ (2,698)	$ (5,767)
Other share purchases			(1.1)	(1.3)
Other share purchases, equity impact			$ 115	$ 121
Exercise of options and employee transactions shares			0	2.8
Exercise of options and employee transactions, equity impact	(1)		$ (35)	$ 153
Equity based compensation shares			8.3	8.5
Equity-based compensation, equity impact	268	242	$ 552	$ 433
Shares delivered to divested business employees Sandoz			0.1
Shares delivered to divested business employees, equity impact Sandoz	2		$ 12
Taxes on treasury shares	12		(8)	(8)
Dividends			(7,624)	(7,255)
Net income	3,246	2,316	5,934	4,609
Other comprehensive income	$ 207	$ 219	$ (1,054)	$ 387
Number of shares outstanding at end of period	2,024.6	2,068.3	2,024.6	2,068.3
Share capital
Disclosure of classes of share capital [line items]
Equity at beginning of period	$ 793	$ 842	$ 825	$ 890
Treasury shares
Disclosure of classes of share capital [line items]
Equity at beginning of period	(17)	(36)	(41)	(92)
Exercise of options and employee transactions, equity impact				2
Equity-based compensation, equity impact	1	1	5	5
Retained earnings
Disclosure of classes of share capital [line items]
Equity at beginning of period	43,834	56,089	49,649	63,540
Exercise of options and employee transactions, equity impact	(1)		(35)	151
Equity-based compensation, equity impact	267	241	547	428
Shares delivered to divested business employees, equity impact Sandoz	2		12
Taxes on treasury shares	12		(8)	(8)
Dividends			(7,624)	(7,255)
Net income	3,246	2,316	5,934	4,609
Total value adjustments
Disclosure of classes of share capital [line items]
Equity at beginning of period	(4,935)	(4,836)	(3,766)	(4,996)
Other comprehensive income	$ 207	$ 219	$ (1,054)	$ 387

Summary of equity attributabl_4

Summary of equity attributable to Novartis AG shareholders (Details 2) Pure in Millions, $ in Billions	1 Months Ended		6 Months Ended
	Jul. 31, 2023 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2024	Jun. 30, 2023
Disclosure of classes of share capital [line items]
Maximal amount of share buyback programm	$ 15	$ 15
Number of shares to be repurchased			8.7	11.7

Financial instruments (Details)

Financial instruments (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Cash and cash equivalents [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	$ 50	$ 50
Cash and cash equivalents [member] | Debt securities
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	50	50
Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	50	50
Level 1 of fair value hierarchy [member] | Cash and cash equivalents [member] | Debt securities
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	50	50
Recurring fair value measurement [member] | Marketable securities, time deposits and derivative financial instruments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	465	355
Recurring fair value measurement [member] | Marketable securities, time deposits and derivative financial instruments [member] | Fund investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	405
Recurring fair value measurement [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	60	355
Recurring fair value measurement [member] | Associated companies at fair value through profit and loss [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	101	101
Recurring fair value measurement [member] | Contingent consideration receivables [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	90	65
Recurring fair value measurement [member] | Fund investments and equity securities current [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	56	125
Recurring fair value measurement [member] | Long term financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	1,628	2,175
Recurring fair value measurement [member] | Long term financial investments [member] | Fund investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	203	190
Recurring fair value measurement [member] | Long term financial investments [member] | Available-for-sale financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	924	1,432
Recurring fair value measurement [member] | Long term financial investments [member] | Contingent consideration receivables [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	501	553
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	405
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Fund investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	405
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Fund investments and equity securities current [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	34	94
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Long term financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	287	803
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Long term financial investments [member] | Fund investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	12	7
Recurring fair value measurement [member] | Level 1 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	275	796
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	60	355
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	60	355
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Long term financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	7	20
Recurring fair value measurement [member] | Level 2 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	7	20
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	101	101
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Contingent consideration receivables [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	90	65
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Fund investments and equity securities current [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	22	31
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	1,334	1,352
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Fund investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	191	183
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Available-for-sale financial investments [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	642	616
Recurring fair value measurement [member] | Level 3 of fair value hierarchy [member] | Long term financial investments [member] | Contingent consideration receivables [member]
Disclosure of fair value measurement of assets [line items]
Financial assets, at fair value	$ 501	$ 553

Financial instruments (Details

Financial instruments (Details 2) - Recurring fair value measurement [member] - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Current financial liabilities at fair value [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	$ (208)	$ (193)
Current financial liabilities at fair value [member] | Contingent consideration payables [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(154)	(14)
Current financial liabilities at fair value [member] | Other financial liabilities [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value			$ (88)
Current financial liabilities at fair value [member] | Derivative financial instruments [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(54)	(91)
Non-current financial liabilities at fair value [member] | Non-current contingent consideration liabilities [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(546)	(389)
Level 2 of fair value hierarchy [member] | Current financial liabilities at fair value [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(54)	(91)
Level 2 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | Derivative financial instruments [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(54)	(91)
Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(154)	(102)
Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | Contingent consideration payables [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	(154)	(14)
Level 3 of fair value hierarchy [member] | Current financial liabilities at fair value [member] | Other financial liabilities [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value			$ (88)
Level 3 of fair value hierarchy [member] | Non-current financial liabilities at fair value [member] | Non-current contingent consideration liabilities [member]
Disclosure of fair value measurement of liabilities [line items]
Financial liabilities, at fair value	$ (546)	$ (389)

Financial instruments (Detail_2

Financial instruments (Details 3) - USD ($) $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about borrowings [line items]
Transfers out of Level 3 of fair value hierarchy, assets		$ (3)
Description of reasons for transfers out of Level 3 of fair value hierarchy, assets	In the first half of 2024, there was one transfer of equity securities from Level 3 to Level 1 for USD 3 million due to Initial Public Offering.
Carrying reported amount fair value disclosure [member]
Disclosure of detailed information about borrowings [line items]
Straight bonds	$ 21,100	21,100	$ 20,600
Fair value disclosure item amounts [member]
Disclosure of detailed information about borrowings [line items]
Straight bonds	19,400	19,400	19,200
Sandoz
Disclosure of detailed information about borrowings [line items]
Gain (loss) on sale of other financial assets	144
Fair value of other financial assets sold	$ 449	$ 61	$ 595

Details to the consolidated s_3

Details to the consolidated statements of cash flows (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Change in provisions and other non-current liabilities	$ 204	$ (53)	$ 367	$ 362
Losses/(gains) on disposal and other adjustments on property, plant and equipment; intangible assets;financial assets; and other non-current assets, net	72	86	142	(216)
Equity-settled compensation expense	257	222	517	412
Income from associated companies	2	2	31	4
Income taxes	595	403	1,036	773
Net financial expense	171	131	386	227
Other	(41)	39	(64)	34
Total	2,400	2,567	4,897	5,249
Property, plant and equipment
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss	228	213	447	465
Right-of-use assets [member]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss	61	68	124	133
Intangible assets
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss	873	1,427	1,905	2,980
Financial assets impaired [member]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss	$ (22)	$ 29	$ 6	$ 75

Details to the consolidated s_4

Details to the consolidated statements of cash flows (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Income taxes paid (refund), classified as operating activities	$ 473	$ 973	$ 1,049	$ 1,268
Income taxes paid refund classified as operating activities discontinued operations	0	57	0	110
Income taxes paid refund classified as operating activities total company	$ 473	$ 1,030	$ 1,049	$ 1,378

Details to the consolidated s_5

Details to the consolidated statements of cash flows (Details 3) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Increase in inventories	$ (18)	$ (185)	$ (146)	$ (546)
Increase in trade receivables	(501)	(447)	(1,421)	(1,147)
Increase/(decrease) in trade payables	(142)	73	(551)	99
Change in other current and non-current assets	(105)	9	(377)	(100)
Change in other current liabilities	1,004	605	744	531
Total	$ 238	$ 55	$ (1,751)	$ (1,163)

Details to the consolidated s_6

Details to the consolidated statements of cash flows (Details 4) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Net cash flows	$ (3,319)	$ (84)	$ (3,598)	$ (107)
Acquisitions
Statement [line items]
Net assets recognized as a result of acquistions of businesses	(3,807)	0	(4,105)	0
Cash and cash equivalents in subsidiary or businesses acquired or disposed	234		236
Contingent consideration payables, net	233		280	(10)
Payments, deferred consideration and other adjustments, net	47	(100)	55	(100)
Net cash flows	(3,293)	(100)	(3,534)	(110)
Divestments
Statement [line items]
Net cash flows	$ (26)	$ 16	$ (64)	$ 3

Revenues and geographic infor_3

Revenues and geographic information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of operating segments [line items]
Net sales to third parties from continuing operations	$ 12,512	$ 11,231	$ 24,341	$ 21,776
Sales to discontinued operations		206		459
Net sales from continuing operations	$ 12,512	$ 11,437	$ 24,341	$ 22,235

Revenues and geographic infor_4

Revenues and geographic information (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 12,512	$ 11,437	$ 24,341	$ 22,235
Net sales (in % of total net sales)	100%	100%	100%	100%
Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	9%		9%
Net sales, change in %, cc	11%		11%
US
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 5,146	$ 4,498	$ 9,734	$ 8,548
Net sales (in % of total net sales)	41%	39%	40%	38%
US | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	14%		14%
Net sales, change in %, cc	14%		14%
Europe [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 3,867	$ 3,688	$ 7,631	$ 7,351
Net sales (in % of total net sales)	31%	32%	31%	33%
Europe [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	5%		4%
Net sales, change in %, cc	6%		5%
Asia/Africa/Australasia [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 2,594	$ 2,425	$ 5,174	$ 4,728
Net sales (in % of total net sales)	21%	21%	21%	21%
Asia/Africa/Australasia [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	7%		9%
Net sales, change in %, cc	13%		15%
Canada and Latin America [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 905	$ 826	$ 1,802	$ 1,608
Net sales (in % of total net sales)	7%	8%	8%	8%
Canada and Latin America [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	10%		12%
Net sales, change in %, cc	15%		15%
Established Markets [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 9,162	$ 8,456	$ 17,650	$ 16,351
Net sales (in % of total net sales)	73%	74%	73%	74%
Established Markets [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	8%		8%
Net sales, change in %, cc	10%		9%
Emerging Growth Markets [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 3,350	$ 2,981	$ 6,691	$ 5,884
Net sales (in % of total net sales)	27%	26%	27%	26%
Emerging Growth Markets [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	12%		14%
Net sales, change in %, cc	16%		19%

Revenues and geographic infor_5

Revenues and geographic information (Details 3) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 12,512	$ 11,437	$ 24,341	$ 22,235
Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	9%		9%
Net sales, change in %, cc	11%		11%
Promoted Brands [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 9,267	7,649	$ 17,731	14,608
Promoted Brands [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	21%		21%
Net sales, change in %, cc	24%		23%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 2,080	1,594	$ 4,110	3,057
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	30%		34%
Net sales, change in %, cc	33%		37%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Entresto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,898	1,516	$ 3,777	2,915
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Entresto [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	25%		30%
Net sales, change in %, cc	28%		32%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Leqvio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 182	78	$ 333	142
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Leqvio [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	133%		135%
Net sales, change in %, cc	134%		137%
Promoted Brands [member] | Immunology [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 2,322	1,950	$ 4,403	3,708
Promoted Brands [member] | Immunology [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	19%		19%
Net sales, change in %, cc	22%		21%
Promoted Brands [member] | Immunology [member] | Cosentyx [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,526	1,272	$ 2,852	2,348
Promoted Brands [member] | Immunology [member] | Cosentyx [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	20%		21%
Net sales, change in %, cc	22%		23%
Promoted Brands [member] | Immunology [member] | Xolair [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 427	362	$ 826	716
Promoted Brands [member] | Immunology [member] | Xolair [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	18%		15%
Net sales, change in %, cc	22%		18%
Promoted Brands [member] | Immunology [member] | Ilaris [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 368	316	$ 724	644
Promoted Brands [member] | Immunology [member] | Ilaris [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	16%		12%
Net sales, change in %, cc	20%		17%
Promoted Brands [member] | Immunology [member] | Other [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1		$ 1
Promoted Brands [member] | Neuroscience [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,225	867	$ 2,234	1,621
Promoted Brands [member] | Neuroscience [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	41%		38%
Net sales, change in %, cc	43%		39%
Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 799	489	$ 1,436	873
Promoted Brands [member] | Neuroscience [member] | Kesimpta [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	63%		64%
Net sales, change in %, cc	65%		66%
Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 349	311	$ 644	620
Promoted Brands [member] | Neuroscience [member] | Zolgensma [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	12%		4%
Net sales, change in %, cc	14%		6%
Promoted Brands [member] | Neuroscience [member] | Aimovig [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 77	67	$ 153	128
Promoted Brands [member] | Neuroscience [member] | Aimovig [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	15%		20%
Net sales, change in %, cc	16%		19%
Promoted Brands [member] | Neuroscience [member] | Other [member]
Disclosure of operating segments [line items]
Net sales from continuing operations			$ 1
Promoted Brands [member] | Oncology [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 3,640	3,238	$ 6,984	6,222
Promoted Brands [member] | Oncology [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	12%		12%
Net sales, change in %, cc	15%		14%
Promoted Brands [member] | Oncology [member] | Kisqali [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 717	493	$ 1,344	908
Promoted Brands [member] | Oncology [member] | Kisqali [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	45%		48%
Net sales, change in %, cc	50%		52%
Promoted Brands [member] | Oncology [member] | Promacta/Revolade [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 544	583	$ 1,064	1,130
Promoted Brands [member] | Oncology [member] | Promacta/Revolade [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(7.00%)		(6.00%)
Net sales, change in %, cc	(5.00%)		(4.00%)
Promoted Brands [member] | Oncology [member] | Tafinlar + Mekinist [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 523	496	$ 997	954
Promoted Brands [member] | Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	5%		5%
Net sales, change in %, cc	9%		7%
Promoted Brands [member] | Oncology [member] | Jakavi [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 471	435	$ 949	849
Promoted Brands [member] | Oncology [member] | Jakavi [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	8%		12%
Net sales, change in %, cc	13%		15%
Promoted Brands [member] | Oncology [member] | Tasigna [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 446	476	$ 841	938
Promoted Brands [member] | Oncology [member] | Tasigna [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(6.00%)		(10.00%)
Net sales, change in %, cc	(4.00%)		(9.00%)
Promoted Brands [member] | Oncology [member] | Pluvicto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 345	240	$ 655	451
Promoted Brands [member] | Oncology [member] | Pluvicto [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	44%		45%
Net sales, change in %, cc	44%		45%
Promoted Brands [member] | Oncology [member] | Lutathera [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 175	150	$ 344	299
Promoted Brands [member] | Oncology [member] | Lutathera [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	17%		15%
Net sales, change in %, cc	17%		16%
Promoted Brands [member] | Oncology [member] | Scemblix [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 164	106	$ 300	182
Promoted Brands [member] | Oncology [member] | Scemblix [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	55%		65%
Net sales, change in %, cc	56%		67%
Promoted Brands [member] | Oncology [member] | Kymriah [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 113	129	$ 233	264
Promoted Brands [member] | Oncology [member] | Kymriah [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(12.00%)		(12.00%)
Net sales, change in %, cc	(11.00%)		(10.00%)
Promoted Brands [member] | Oncology [member] | Piqray/Vijoice [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 120	130	$ 229	246
Promoted Brands [member] | Oncology [member] | Piqray/Vijoice [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(8.00%)		(7.00%)
Net sales, change in %, cc	(7.00%)		(6.00%)
Promoted Brands [member] | Oncology [member] | Fabhalta [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 22		$ 28
Promoted Brands [member] | Oncology [member] | Other [member]
Disclosure of operating segments [line items]
Net sales from continuing operations				1
Established Brands [member] | Established Brands [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 3,245	3,788	$ 6,610	7,627
Established Brands [member] | Established Brands [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(14.00%)		(13.00%)
Net sales, change in %, cc	(13.00%)		(12.00%)
Established Brands [member] | Established Brands [member] | Sandostatin Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 313	331	$ 668	660
Established Brands [member] | Established Brands [member] | Sandostatin Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(5.00%)		1%
Net sales, change in %, cc	(4.00%)		3%
Established Brands [member] | Established Brands [member] | Lucentis [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 275	395	$ 589	811
Established Brands [member] | Established Brands [member] | Lucentis [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(30.00%)		(27.00%)
Net sales, change in %, cc	(28.00%)		(26.00%)
Established Brands [member] | Established Brands [member] | Exforge Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 178	184	$ 370	370
Established Brands [member] | Established Brands [member] | Exforge Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(3.00%)		0%
Net sales, change in %, cc	1%		3%
Established Brands [member] | Established Brands [member] | Gilenya [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 138	269	$ 313	501
Established Brands [member] | Established Brands [member] | Gilenya [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(49.00%)		(38.00%)
Net sales, change in %, cc	(47.00%)		(36.00%)
Established Brands [member] | Established Brands [member] | Diovan Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 160	155	$ 300	313
Established Brands [member] | Established Brands [member] | Diovan Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	3%		(4.00%)
Net sales, change in %, cc	9%		1%
Established Brands [member] | Established Brands [member] | Galvus Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 150	175	$ 299	358
Established Brands [member] | Established Brands [member] | Galvus Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(14.00%)		(16.00%)
Net sales, change in %, cc	(5.00%)		(9.00%)
Established Brands [member] | Established Brands [member] | Contract manufacturing [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 271	339	$ 550	714
Established Brands [member] | Established Brands [member] | Contract manufacturing [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(20.00%)		(23.00%)
Net sales, change in %, cc	(19.00%)		(23.00%)
Established Brands [member] | Established Brands [member] | Other [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,760	$ 1,940	$ 3,521	$ 3,900
Established Brands [member] | Established Brands [member] | Other [member] | Change over period [member]
Disclosure of operating segments [line items]
Net sales, change in %	(9.00%)		(10.00%)
Net sales, change in %, cc	(10.00%)		(10.00%)

Revenues and geographic infor_6

Revenues and geographic information (Details 4) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 12,512	$ 11,437	$ 24,341	$ 22,235
Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	9%		9%
Net sales, change in %, cc	11%		11%
Top 20 products [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 9,998		$ 19,326
Top 20 products [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	15%		16%
Net sales, change in %, cc	18%		18%
Rest of portfolio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 2,514		$ 5,015
Rest of portfolio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(10.00%)		(11.00%)
Net sales, change in %, cc	(10.00%)		(10.00%)
Promoted Brands [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 9,267	7,649	$ 17,731	14,608
Promoted Brands [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	21%		21%
Net sales, change in %, cc	24%		23%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 2,080	1,594	$ 4,110	3,057
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	30%		34%
Net sales, change in %, cc	33%		37%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Entresto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,898	1,516	$ 3,777	2,915
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Entresto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	25%		30%
Net sales, change in %, cc	28%		32%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Leqvio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 182	78	$ 333	142
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Leqvio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	133%		135%
Net sales, change in %, cc	134%		137%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,898		$ 3,777
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	25%		30%
Net sales, change in %, cc	28%		32%
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 182		$ 333
Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	133%		135%
Net sales, change in %, cc	134%		137%
Promoted Brands [member] | Immunology [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 2,322	1,950	$ 4,403	3,708
Promoted Brands [member] | Immunology [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	19%		19%
Net sales, change in %, cc	22%		21%
Promoted Brands [member] | Immunology [member] | Cosentyx [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,526	1,272	$ 2,852	2,348
Promoted Brands [member] | Immunology [member] | Cosentyx [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	20%		21%
Net sales, change in %, cc	22%		23%
Promoted Brands [member] | Immunology [member] | Xolair [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 427	362	$ 826	716
Promoted Brands [member] | Immunology [member] | Xolair [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	18%		15%
Net sales, change in %, cc	22%		18%
Promoted Brands [member] | Immunology [member] | Ilaris [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 368	316	$ 724	644
Promoted Brands [member] | Immunology [member] | Ilaris [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	16%		12%
Net sales, change in %, cc	20%		17%
Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,526		$ 2,852
Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	20%		21%
Net sales, change in %, cc	22%		23%
Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 427		$ 826
Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	18%		15%
Net sales, change in %, cc	22%		18%
Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 368		$ 724
Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	16%		12%
Net sales, change in %, cc	20%		17%
Promoted Brands [member] | Neuroscience [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,225	867	$ 2,234	1,621
Promoted Brands [member] | Neuroscience [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	41%		38%
Net sales, change in %, cc	43%		39%
Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 799	489	$ 1,436	873
Promoted Brands [member] | Neuroscience [member] | Kesimpta [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	63%		64%
Net sales, change in %, cc	65%		66%
Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 349	311	$ 644	620
Promoted Brands [member] | Neuroscience [member] | Zolgensma [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	12%		4%
Net sales, change in %, cc	14%		6%
Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 799		$ 1,436
Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	63%		64%
Net sales, change in %, cc	65%		66%
Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 349		$ 644
Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	12%		4%
Net sales, change in %, cc	14%		6%
Promoted Brands [member] | Oncology [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 3,640	3,238	$ 6,984	6,222
Promoted Brands [member] | Oncology [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	12%		12%
Net sales, change in %, cc	15%		14%
Promoted Brands [member] | Oncology [member] | Kisqali [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 717	493	$ 1,344	908
Promoted Brands [member] | Oncology [member] | Kisqali [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	45%		48%
Net sales, change in %, cc	50%		52%
Promoted Brands [member] | Oncology [member] | Promacta/Revolade [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 544	583	$ 1,064	1,130
Promoted Brands [member] | Oncology [member] | Promacta/Revolade [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(7.00%)		(6.00%)
Net sales, change in %, cc	(5.00%)		(4.00%)
Promoted Brands [member] | Oncology [member] | Tafinlar + Mekinist [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 523	496	$ 997	954
Promoted Brands [member] | Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	5%		5%
Net sales, change in %, cc	9%		7%
Promoted Brands [member] | Oncology [member] | Tasigna [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 446	476	$ 841	938
Promoted Brands [member] | Oncology [member] | Tasigna [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(6.00%)		(10.00%)
Net sales, change in %, cc	(4.00%)		(9.00%)
Promoted Brands [member] | Oncology [member] | Pluvicto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 345	240	$ 655	451
Promoted Brands [member] | Oncology [member] | Pluvicto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	44%		45%
Net sales, change in %, cc	44%		45%
Promoted Brands [member] | Oncology [member] | Lutathera [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 175	150	$ 344	299
Promoted Brands [member] | Oncology [member] | Lutathera [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	17%		15%
Net sales, change in %, cc	17%		16%
Promoted Brands [member] | Oncology [member] | Scemblix [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 164	106	$ 300	182
Promoted Brands [member] | Oncology [member] | Scemblix [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	55%		65%
Net sales, change in %, cc	56%		67%
Promoted Brands [member] | Oncology [member] | Jakavi [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 471	435	$ 949	849
Promoted Brands [member] | Oncology [member] | Jakavi [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	8%		12%
Net sales, change in %, cc	13%		15%
Promoted Brands [member] | Oncology [member] | Kymriah [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 113	129	$ 233	264
Promoted Brands [member] | Oncology [member] | Kymriah [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(12.00%)		(12.00%)
Net sales, change in %, cc	(11.00%)		(10.00%)
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Kisqali [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 717		$ 1,344
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	45%		48%
Net sales, change in %, cc	50%		52%
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 544		$ 1,064
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(7.00%)		(6.00%)
Net sales, change in %, cc	(5.00%)		(4.00%)
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 523		$ 997
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	5%		5%
Net sales, change in %, cc	9%		7%
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tasigna [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 446		$ 841
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(6.00%)		(10.00%)
Net sales, change in %, cc	(4.00%)		(9.00%)
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 345		$ 655
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	44%		45%
Net sales, change in %, cc	44%		45%
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Lutathera [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 175		$ 344
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	17%		15%
Net sales, change in %, cc	17%		16%
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Scemblix [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 164		$ 300
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	55%		65%
Net sales, change in %, cc	56%		67%
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Jakavi [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 471		$ 949
Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	8%		12%
Net sales, change in %, cc	13%		15%
Established Brands [member] | Established Brands [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 3,245	3,788	$ 6,610	7,627
Established Brands [member] | Established Brands [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(14.00%)		(13.00%)
Net sales, change in %, cc	(13.00%)		(12.00%)
Established Brands [member] | Established Brands [member] | Sandostatin Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 313	331	$ 668	660
Established Brands [member] | Established Brands [member] | Sandostatin Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(5.00%)		1%
Net sales, change in %, cc	(4.00%)		3%
Established Brands [member] | Established Brands [member] | Lucentis [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 275	395	$ 589	811
Established Brands [member] | Established Brands [member] | Lucentis [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(30.00%)		(27.00%)
Net sales, change in %, cc	(28.00%)		(26.00%)
Established Brands [member] | Established Brands [member] | Exforge Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 178	184	$ 370	370
Established Brands [member] | Established Brands [member] | Exforge Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(3.00%)		0%
Net sales, change in %, cc	1%		3%
Established Brands [member] | Established Brands [member] | Gilenya [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 138	269	$ 313	501
Established Brands [member] | Established Brands [member] | Gilenya [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(49.00%)		(38.00%)
Net sales, change in %, cc	(47.00%)		(36.00%)
Established Brands [member] | Established Brands [member] | Diovan Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 160	155	$ 300	313
Established Brands [member] | Established Brands [member] | Diovan Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	3%		(4.00%)
Net sales, change in %, cc	9%		1%
Established Brands [member] | Established Brands [member] | Galvus Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 150	175	$ 299	358
Established Brands [member] | Established Brands [member] | Galvus Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(14.00%)		(16.00%)
Net sales, change in %, cc	(5.00%)		(9.00%)
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 313		$ 668
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(5.00%)		1%
Net sales, change in %, cc	(4.00%)		3%
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 275		$ 589
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(30.00%)		(27.00%)
Net sales, change in %, cc	(28.00%)		(26.00%)
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 178		$ 370
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(3.00%)		0%
Net sales, change in %, cc	1%		3%
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gilenya [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 138		$ 313
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gilenya [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(49.00%)		(38.00%)
Net sales, change in %, cc	(47.00%)		(36.00%)
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 160		$ 300
Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	3%		(4.00%)
Net sales, change in %, cc	9%		1%
US
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 5,146	$ 4,498	$ 9,734	$ 8,548
US | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	14%		14%
Net sales, change in %, cc	14%		14%
US | Top 20 products [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 4,630		$ 8,725
US | Top 20 products [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	23%		22%
US | Rest of portfolio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 516		$ 1,009
US | Rest of portfolio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(29.00%)		(29.00%)
US | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 947		$ 1,895
US | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	25%		30%
US | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 94		$ 168
US | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	114%		107%
US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 868		$ 1,529
US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	34%		30%
US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 194		$ 360
US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	19%		18%
US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 555		$ 970
US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	49%		45%
US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 134		$ 238
US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	60%		23%
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Kisqali [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 375		$ 688
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	67%		69%
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 283		$ 549
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(10.00%)		(7.00%)
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 202		$ 386
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	3%		(1.00%)
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tasigna [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 230		$ 404
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(1.00%)		(9.00%)
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 295		$ 576
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	30%		33%
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Lutathera [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 124		$ 241
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	17%		15%
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Scemblix [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 105		$ 193
US | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	35%		39%
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 187		$ 426
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(8.00%)		3%
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1		$ 5
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(75.00%)		(38.00%)
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gilenya [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 30		$ 82
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gilenya [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(71.00%)		(55.00%)
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 6		$ 15
US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(50.00%)		(44.00%)
Rest of the world [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 7,366		$ 14,607
Rest of the world [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	6%		7%
Net sales, change in %, cc	9%		10%
Rest of the world [member] | Top 20 products [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 5,368		$ 10,601
Rest of the world [member] | Top 20 products [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	10%		12%
Net sales, change in %, cc	14%		15%
Rest of the world [member] | Rest of portfolio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 1,998		$ 4,006
Rest of the world [member] | Rest of portfolio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(3.00%)		(4.00%)
Net sales, change in %, cc	(3.00%)		(3.00%)
Rest of the world [member] | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 951		$ 1,882
Rest of the world [member] | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Entresto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	25%		29%
Net sales, change in %, cc	30%		34%
Rest of the world [member] | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 88		$ 165
Rest of the world [member] | Promoted Brands [member] | Cardiovascular, renal and metabolic [member] | Top 20 products [member] | Leqvio [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	159%		170%
Net sales, change in %, cc	165%		175%
Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 658		$ 1,323
Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	6%		13%
Net sales, change in %, cc	10%		16%
Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 427		$ 826
Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	18%		15%
Net sales, change in %, cc	22%		18%
Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 174		$ 364
Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	14%		7%
Net sales, change in %, cc	22%		16%
Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 244		$ 466
Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	110%		127%
Net sales, change in %, cc	118%		133%
Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 215		$ 406
Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(5.00%)		(5.00%)
Net sales, change in %, cc	(3.00%)		(3.00%)
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Kisqali [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 342		$ 656
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	27%		31%
Net sales, change in %, cc	35%		37%
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 261		$ 515
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(3.00%)		(5.00%)
Net sales, change in %, cc	1%		(1.00%)
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 321		$ 611
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	7%		8%
Net sales, change in %, cc	13%		13%
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tasigna [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 216		$ 437
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(11.00%)		(12.00%)
Net sales, change in %, cc	(7.00%)		(9.00%)
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 50		$ 79
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Pluvicto [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	285%
Net sales, change in %, cc	274%
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Lutathera [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 51		$ 103
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Lutathera [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	16%		16%
Net sales, change in %, cc	19%		17%
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Scemblix [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 59		$ 107
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Scemblix [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	111%		149%
Net sales, change in %, cc	112%		154%
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Jakavi [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 471		$ 949
Rest of the world [member] | Promoted Brands [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	8%		12%
Net sales, change in %, cc	13%		15%
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 126		$ 242
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(2.00%)		(2.00%)
Net sales, change in %, cc	3%		2%
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 275		$ 589
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Lucentis [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(30.00%)		(27.00%)
Net sales, change in %, cc	(28.00%)		(26.00%)
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 177		$ 365
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(2.00%)		1%
Net sales, change in %, cc	2%		4%
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gilenya [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 108		$ 231
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gilenya [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	(35.00%)		(27.00%)
Net sales, change in %, cc	(31.00%)		(25.00%)
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]
Disclosure of operating segments [line items]
Net sales from continuing operations	$ 154		$ 285
Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member]
Disclosure of operating segments [line items]
Revenue from sale of goods, change in percent	8%		0%
Net sales, change in %, cc	15%		5%

Revenues and geographic infor_7

Revenues and geographic information (Details 5) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of operating segments [line items]
Profit sharing income	$ 268	$ 246	$ 482	$ 445
Royalty income	5	19	24	41
Milestone income	14	25	20	28
Other	73	18	125	43
Other revenues	$ 360	$ 308	$ 651	$ 557

Other interim disclosures (Deta

Other interim disclosures (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Discontinued operations [member]
Statement [line items]
Property, plant and equipment impairment charges		$ (1)		$ (2)
Property, plant and equipment impairment reversal		1		1
Property, plant and equipment depreciation charge		(48)		(99)
Right-of-use assets depreciation charge		(10)		(18)
Intangible assets impairment charges		(1)		(13)
Intangible assets amortization charge		(56)		(111)
Impairment loss recognised in profit or loss, right of use assets				0
Reversal impairment loss recognised in profit or loss, right of use assets				0
Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill				0
Accumulated depreciation, amortisation and impairment [member]
Statement [line items]
Property, plant and equipment impairment charges	$ (9)	(31)	$ (10)	(58)
Property, plant and equipment impairment reversal		39		48
Property, plant and equipment depreciation charge	(219)	(222)	(437)	(455)
Right-of-use assets depreciation charge	(61)	(68)	(124)	(133)
Intangible assets impairment charges	(37)	(454)	(194)	(927)
Intangible assets amortization charge	$ (836)	$ (974)	(1,711)	(2,053)
Impairment loss recognised in profit or loss, right of use assets			0
Reversal impairment loss recognised in profit or loss, right of use assets			0
Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill			$ 0
Acquired research and development [member] | Accumulated depreciation, amortisation and impairment [member]
Statement [line items]
Intangible assets impairment charges				(0.3)
Currently marketed products [member] | Accumulated depreciation, amortisation and impairment [member]
Statement [line items]
Intangible assets impairment charges				$ (300)

Other interim disclosures (De_2

Other interim disclosures (Details 2) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Additions to property, plant and equipment	$ 283	$ 211	$ 506	$ 388
Additions to right-of-use assets	69	49	97	192
Additions to intangible assets and goodwill	$ 512	$ 521	$ 1,175	$ 716

Other interim disclosures (De_3

Other interim disclosures (Details 3) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 01, 2024	May 31, 2024
3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]
Disclosure of detailed information about borrowings [line items]
Disclosure of detailed information about borrowings	In the second quarter of 2024, Novartis repaid the 3.4%
Borrowings, interest rate	3.40%
Borrowings, original currency	USD
Notional amount	$ 2,150
Borrowings, issuance date	2014
Borrowings, lender	Novartis Capital Corporation, USA
1.600% CHF 650 million bond 2027 of Novartis AG Basel Switzerland, issued at 100.138% [member]
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	1.60%
Borrowings, original currency	CHF
Notional amount	$ 650
Borrowings, maturity	2027
Borrowings, lender	Novartis AG, Basel, Switzerland
Borrowings, issue price	100.138%
Bonds issued	$ 723
1.650% CHF 435 million bond 2031 of Novartis AG Basel Switzerland, issued at 100.148% [member]
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	1.65%
Borrowings, original currency	CHF
Notional amount	$ 435
Borrowings, maturity	2031
Borrowings, lender	Novartis AG, Basel, Switzerland
Borrowings, issue price	100.148%
Bonds issued	$ 483
1.750% CHF 645 million bond 2034 of Novartis AG Basel Switzerland, issued at 100.229% [member]
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	1.75%
Borrowings, original currency	CHF
Notional amount	$ 645
Borrowings, maturity	2034
Borrowings, lender	Novartis AG, Basel, Switzerland
Borrowings, issue price	100.229%
Bonds issued	$ 717
1.850% CHF 280 million bond 2040 of Novartis AG Basel Switzerland, issued at 100.268% [member]
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	1.85%
Borrowings, original currency	CHF
Notional amount	$ 280
Borrowings, maturity	2040
Borrowings, lender	Novartis AG, Basel, Switzerland
Borrowings, issue price	100.268%
Bonds issued	$ 311
1.850% CHF 190 million bond 2049 of Novartis AG Basel Switzerland, issued at 100.149% [member]
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	1.85%
Borrowings, original currency	CHF
Notional amount	$ 190
Borrowings, maturity	2049
Borrowings, lender	Novartis AG, Basel, Switzerland
Borrowings, issue price	100.149%
Bonds issued	$ 211
Replacement of credit facility with a syndicate of banks [member]
Disclosure of detailed information about borrowings [line items]
Disclosure of detailed information about borrowings	In May 2024, Novartis replaced its existing USD 6.0 billion credit facility with a syndicate of banks (which was undrawn at its replacement date and December 31, 2023 and had a maturity date of September 2025) with a new USD 6.0 billion credit facility with a syndicate of banks. This credit facility is intended to be used as a backstop for the US commercial paper program. This facility matures in May 2029, and was undrawn as at June 30, 2024.
Borrowings credit facility committed		$ 6,000	$ 6,000

Other interim disclosures (De_4

Other interim disclosures (Details 4) $ in Millions	Jun. 30, 2024 USD ($)
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under long-term research and development agreements	$ 7,199
Not later than one year
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under pending longterm research agreements	100
Commitments under long-term research and development agreements	226
Later than one year and not later than two years [member]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under long-term research and development agreements	209
Later than two years and not later than three years [member]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under pending longterm research agreements	100
Commitments under long-term research and development agreements	460
Later than three years and not later than four years [member]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under long-term research and development agreements	396
Later than four years and not later than five years [member]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under pending longterm research agreements	100
Commitments under long-term research and development agreements	566
Later than five years and not later than six years [member]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under pending longterm research agreements	100
Commitments under long-term research and development agreements	487
Later than six years [member]
Schedule for commitments under research and development and other intangible asset purchase [line items]
Commitments under pending longterm research agreements	1,000
Commitments under long-term research and development agreements	$ 4,855

Discontinued operations (Detail

Discontinued operations (Details) $ in Millions		3 Months Ended		6 Months Ended
	Oct. 03, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Statement [line items]
Net sales to third parties		$ 12,512	$ 11,231	$ 24,341	$ 21,776
Sales to other segments			206		459
Net sales		12,512	11,437	24,341	22,235
Other revenue		360	308	651	557
Cost of goods sold		(3,173)	(3,342)	(6,269)	(6,333)
Gross profit		9,699	8,403	18,723	16,459
Selling, general and administration		(3,091)	(3,091)	(5,931)	(5,982)
Research and development		(2,367)	(2,304)	(4,788)	(4,879)
Other income		273	135	522	1,098
Other expense		(500)	(336)	(1,139)	(1,271)
Operating income of discontinued operations		4,014	2,807	7,387	5,425
Loss from associated companies		(2)	(2)	(31)	(4)
Interest expense		(246)	(216)	(467)	(416)
Other financial income and expense		75	85	81	189
Income before taxes		3,841	2,674	6,970	5,194
Income taxes		$ (595)	(403)	$ (1,036)	(773)
Gain on distribution of Sandoz Group AG to Novartis AG shareholders	$ 5,860
Net income from discontinued operations			46		190
Discontinued operations [member]
Statement [line items]
Net sales to third parties			2,391		4,799
Sales to other segments			58		153
Net sales			2,449		4,952
Other revenue			6		12
Cost of goods sold			(1,263)		(2,551)
Gross profit			1,192		2,413
Selling, general and administration			(595)		(1,147)
Research and development			(222)		(441)
Other income			21		28
Other expense			(283)		(502)
Operating income of discontinued operations			113		351
Loss from associated companies					1
Interest expense			(8)		(19)
Other financial income and expense			(10)		(18)
Income before taxes			95		315
Income taxes			(49)		(125)
Net income from discontinued operations			$ 46		$ 190
Applicable tax rate from discontinued operations			31.50%		28.60%
Number of Franchises					2

Discontinued operations (Deta_2

Discontinued operations (Details 2) - Discontinued operations [member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Statement [line items]
Interest income		$ 1
Property, plant and equipment depreciation charge	$ (48)	(99)
Right-of-use assets depreciation charge	(10)	(18)
Intangible assets amortization charge	(56)	(111)
Property, plant and equipment impairment charges	(1)	(2)
Intangible assets impairment charges	(1)	(13)
Property, plant and equipment impairment reversal	1	1
Additions to restructuring provisions	(11)	(16)
Equity-based compensation of Novartis equity plans	$ (18)	(36)
Reversal impairment loss recognised in profit or loss, right of use assets		0
Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill		$ 0

Discontinued operations (Deta_3

Discontinued operations (Details 3) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement [line items]
Additions to property, plant and equipment	$ 283	$ 211	$ 506	$ 388
Additions to right-of-use assets	69	49	97	192
Additions to intangible assets and goodwill	$ 512	521	$ 1,175	716
Discontinued operations [member]
Statement [line items]
Additions to property, plant and equipment		82		160
Additions to right-of-use assets		24		33
Additions to intangible assets and goodwill		$ 35		$ 56